The impact of alcohol consumption on hospital treatment cost and length of stay for non-alcohol-related diseases : a retrospective cross sectional comparison of patients with alcohol-related co-morbidities and those without alcohol-related co-morbidities by Moumin, Caliph Omar
The Impact of Alcohol Consumption ON Hospital Treatment 
Cost and Length of Stay for Non-alcohol-related Diseases:  
A retrospective cross sectional comparison of patients with alcohol-related co-
morbidities and those without alcohol-related co-morbidities 
 





Department of Health Management and Health Economics 
The Faculty of Medicine 
UNIVERSITY OF OSLO 
 

















© Caliph Moumin 
2012 





































Declaration: I am hereby declaring that this thesis is a result of my own work and prepared 
for completion of my master programme. Previous literatures are properly recognized and 
cited in accordance with ethical and universally acceptable standards. The findings and 






Background: Alcohol is a commodity which contains toxic substances like ethanol and 
methanol (WHO, 1994). It is a primary cause of negative health effects, and a main risk factor 
for many other major chronic diseases (Rehm et al., 2009; WHO, 2011b). The health and 
economic burden attributable to alcohol is enormous thorough the globe (Rehm et al., 2009; 
Rutherford and McNeill, 2009). The unknown economic losses of alcohol, because of the 
difficulties in estimation, could be huge and misleading if not estimated with conscious 
(Baumberg, 2006). The intricateness and multidimensional correlations between alcohol 
consumption and health problems attributable to alcohol (Rehm et al., 2010) makes such 
estimations even more obscure. 
Objective: The objective of this study was to find whether there is higher treatment cost and 
longer length of hospital stay (LOS) for those with alcohol related co-morbidities than those 
without these co-morbidities, for the treatments of the pathologically non-alcohol-related 
diagnoses. 
Method: Negative binomial regression model and generalized linear regression model were 
applied to LOS and treatment cost respectively for 8 diagnoses selected from Norwegian 
patient registry 2008. 
Results: Patients with alcohol-related diseases had statistically significant higher treatment 
cost for all 8 diagnoses among males. Four diagnoses of which had longer LOS for females 
with alcohol-related diagnoses had also higher treatment cost amongst females. The longer 
LOS for erysipelas (A46), unspecified chest pain (R074), and pain localized to upper 
abdomen (R101) were found statistically significant for both women and men with alcohol-
related diseases. In addition women with alcohol-related diagnoses had statistically significant 
longer LOS for unspecified asthma (J459) and acute tubule-interstitial nephritis (N10) than 
other women, whereas men identified as alcohol consumers were found to have longer LOS 
for volume depletion (E86) and other unspecified convulsion (R568) than other men. 
Conclusions: Alcohol related diseases co-occur with other diseases; co-morbidity of diseases 
is associated with increased health care costs; the result of this study implicates that patients 
with alcohol related diseases had higher treatment cost with longer LOS for the treatment of 
the non-alcohol related diagnoses. If this is the case it would mean that economic burden of 
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1.  Introduction 
Concerns of the health, economic and social consequences attributable to alcohol are not new 
phenomenon; studying these consequences dates back  for centuries if not since the beginning 
of the recorded history of alcohol consumption (Melberg, 2006; Rehm et al., 2009). But the 
alarming voices of these consequences of alcohol are more vivid and louder ever before. The 
international disease classification code known as ‘ICD-10’ includes the word ‘alcohol’ to 
more than 230 three-digit or four-digit codes of health problems either as their prime or partial 
cause (Rehm et al., 2009). This triggered parallel increased concerns about the economic and 
social cost of alcohol burden. Studies about the economic consequences of alcohol have been 
accumulated throughout the globe. Very recent ones are conducted by Schwappach et al. 
(2012); Stevenson et al. (2012); Scarborough et al. (2011); Popova et al. (2011).  
What all these and other economic evaluation studies of alcohol related problems have in 
common are concerns about the increasing loss of scarce economic resources that are fully or 
partially associated to alcohol problems. According to the Institute of Alcohol Studies (IAS, 
2007) factsheet, the social cost of alcohol in Europe is more than the welfare and security 
spending. Direct health care costs, productivity loss, the cost of accidents related to alcohol, 
the cost of welfare care for disability-adjusted-life-years (DALY) and other direct and indirect 
costs are attributed to alcohol consumption (Godfrey, 2004). 
 While it is worth noting the economic benefit of alcohol industry in terms of employment and 
its contribution to the gross domestic product(GDP), the unknown social losses of alcohol, 
because of the difficulties in estimating societal loss of alcohol, could outweigh these benefits 
if not controlled properly (Baumberg, 2006; IAS, 2007). The intricateness and 
multidimensional correlations between alcohol intake and health problems (Rehm et al., 2010) 
makes such estimations even more obscure. 
Alcohol prevention policies, like alcohol taxation (one of the main and most effective policies 
for reducing alcohol consumption), are determined by the economic and societal cost 
evaluation of alcohol. Failure to reflect the true cost of alcohol in cost-benefit analysis could 
affect alcohol taxation, and the effectiveness of the policy. Most of the economic evaluations 
of alcohol consumption focus on certain illnesses, which the causal association with alcohol 
intake were already discovered. However, there are many other health conditions which such 
kind of associations are not discovered yet. Little is known about how alcohol through alcohol 




costly to treat patients with alcohol problems who were diagnosed with alcohol-related co-
morbidity from other non-alcohol-related health problems? If this was the case, it would mean 
the societal cost of alcohol was underestimated; thus by not capturing the true cost of alcohol 
could lead ineffective preventive policies. In other words, undervaluing the economic loss of 
alcohol affects not only the results of the cost-benefit analyses, but also the policy 
implications of these studies to effectively reduce alcohol consumption by taxation and other 
preventive policies.  
The objective of this study was to find whether there are treatment cost and length of hospital 
stay (LOS) variations between patients with alcohol-related co-morbidities and those without 
alcohol-related co-morbidities for the treatments of non-alcohol-related diagnoses as 
illustrated in figure 1.1 below. Observational retrospective data of 2008 Norwegian patient 
registry (NPR) were used to analyze and compare the LOS and hospital treatment costs of 
patients with alcohol-related problems to other patients.   
Figure 1-1: Is the treatment cost and length of hospital stay different between those with alcohol co-morbidity and 
those without it? 
 
Although the analysis of this study was limited to the hospital cost, yet it is an important 
contribution to previous studies conducted about the economic evaluation of alcohol costs and 
alcohol policies. This study looked at the cost of alcohol from a new perspective. The bulk 
economic evaluations of alcohol burden studies have contributed to understanding of how 
huge economic loss of alcohol burden is. However, no available studies of a broader 
perspective of alcohol loss by including not only the economic burden of diseases discovered 
association with alcohol but also the effect of alcohol and/or alcohol co-morbidity to other 




1.1 Structure of the Study 
The study contains seven chapters, chapter one introduces the gap and importance of this 
study. Chapter two extensively explains the alcohol problems both in Norway, Europe and the 
worldwide. Chapter three presents the previous theories of alcohol use, economic evaluations 
and the problem of co-morbidity. Chapter four describes the data structure and models. 
Chapter five presents the results and findings of the study. Chapter six presents the 
discussions and analysis. And brief conclusion of the study is presented in chapter seven. 
1.2 Ethics 
The study was based on patient record; which could be sensitive if personal information is 
revealed. However, personal identity was excluded from the dataset. Hypothetical identifiers 
were assigned to observations, and age was included in categorical form. Neither the author 
nor readers could identify the personal identity of the patients. Analysis was made 
anonymously without revealing any personal information. Moreover, the dataset was used for 
other studies conducted by the department of Health Economics and Management at 
















2.  Background 
2.1 Alcohol Metabolism Process and Causation Model 
Alcohol is one of the oldest and most widely consumed commodities by human beings since 
ancient era (Horton, 1991; Room et al., 2005). It consists of large group of organic 
compounds like ethanol and methanol which are toxic and endanger the health of the 
consumers (WHO, 1994). It is both a primary cause of negative effects like trauma, alcohol-
use disorder, liver cirrhosis, and alcohol-induced pancreatitis; and it is a main risk factor for 
many other major chronic diseases like cancer, cardiovascular diseases (Rehm et al., 2009; 
WHO, 2011b). The risk of the toxic substance (ethanol) is increased by alcohol metabolism 
pathways; the process of extracting and absorption of alcohol from the blood.  
Most alcohol metabolism happens in the liver organ, however, there are many body organs 
like esophagus, small intestine, veins, stomach, bowels, brain and other important organs of 
the body which either involve the metabolism process or the distribution of alcohol before and 
after metabolism process begin (Zakhari, 2006). During this metabolism process alcohol 
impairs the tissues of these body organs (Koop, 2006), resulting deaths and disabilities among 
alcohol consumers throughout the world due to large number of different medical conditions 
which directly or indirectly originate from this metabolism process (Zakhari, 2006). The 
detrimental effect of alcohol is high in the liver organ because of its main role for absorption 
and extraction of the toxic substances of alcohol from the body (Clemens, 2006).  
The causal associations between alcohol consequences and alcohol consumption are very 
intricate and multidimensional (Rehm et al., 2010). The causation model shown in Figure 2-1 
below ( adapted from Rehm et al. (2010)  illustrates how volume; pattern; and quality of 
alcohol consumed participate to chronic and acute health conditions. While increase in 
volume and pattern of drinking has positive association with alcohol related consequences, so 
is the low quality with high concentration of methanol and ethanol; usually home made 
alcohol beverages (Rehm et al., 2010; GreenFacts, 2006b). Rehm et al. (2003b) argued that 
alcohol consumption causes the detrimental health consequences through three intermediary 
means namely intoxication, dependence and direct biological effects. Intoxication relates to 
alcohol problems such traffic and other accidents, dependence relates to the problem of 




Figure 2-1: Causation Model, Intermediary mechanisms and long-term consequences of alcohol consumption 
 
alcohol consumption (Rehm et al., 2003b). While these three intermediary mechanisms are 
not mutually exclusive, however such classifications are helpful for reducing the complexity 
problem of the relationship between alcohol consumption and its consequences. The volume, 
pattern and quality of alcohol beverages through these three and other intermediary 
mechanisms lead to negative health outcome which later results death. 
2.2 Alcohol Consumption 
Although alcohol is widely consumed worldwide, there are differences in drinking habits and 
attitudes (Bloomfield et al., 2003) as well as alcohol production process in terms of how it is 
produced and where it is produced (domestic or abroad). This resulted in variations of alcohol 
concentration. However, it is important to measure the alcohol consumption of a country with 
respect to other countries. This necessitates the need for common measurement which can be 
applied to all countries. One of the mainly used measurements is adult per capita alcohol 
consumption (APC), which is the per capita of pure alcohol (the ethanol)  intake in liters by 
given adult population of above 15 years (WHO, 2011b). This common measurement helps 
for international comparison of the factors influencing the drinking habits as well as the 
political actions towards the provision of reducing alcohol consumption (Bloomfield et al., 





2.2.1 Alcohol Consumption Level in Norway 
 
Figure 2-2: Alcohol Consumption level and Trends in Norway 
 
Source: adapted from WHO (2011c) 
Although Norway has the strictest alcohol control policy amongst the Organization for 
Economic Cooperation and Development (OECD) (Brand et al., 2007; WHO, 2011c); 
however,  according to the Norwegian institute of public health  (NIPH, 2010) factsheet of 
alcohol consumption, the consumption of alcohol has been increasing for the past four 
decades. The alcohol consumption trend of Norway for the past half century; and level and 
changes of alcohol consumption for the last four decades are presented in the figure 2.2 above 
(WHO, 2011c). Figure 2.3 below also indicates an increasing alcohol consumption in Norway 
(OECD, 2011a). The alcohol consumption in Norway, which is 6.7 litre of pure alcohol per 
capita of the population above 15 years, is one the lowest level of alcohol consumption in 
OECD countries as shown in Figure 2-3 (OECD, 2011b). But, it is also one of the few 
countries which had an increased alcohol consumption level between 1980 and 2009. 
Contrary to the 9% reduction of average alcohol consumption in OECD countries, there was 
12% increase of alcohol consumption in Norway during this period. The impacts of 
globalization, internet, regional integration, as well as changes of income have no doubt 




Figure 2-3: Alcohol consumption, population aged 15 and above, 2009 (or nearest year) and changes between 1980 
and 2009 
 
Despite the fact that alcohol consumption in Norway increased during this period, it is 
important to note that this increment is minimal both in terms of yearly trend and OECD 
country comparison as shown in figure 2.2 and figure 2.3 respectively. Even though there was 
decreased trend of alcohol consumption in many OECD countries, the alcohol consumption 
level of Norway is still much lower than most of the other OECD countries.  
2.2.2 Global Alcohol Consumption 
About one-third of the world’s total population drinks alcohol (Greenfacts, 2006a). Even 
though alcohol problems’ prevention policy is among the highly prioritized in public health 
issues (WHO, 2012), alcohol consumption is increasing globally (WHO, 2011a) as shown in 
the Figure 2-4 below. According to WHO (2011a) Global Information System on Alcohol and 
Health (GISAH), the global total adults (15+ years) per capita consumption of pure alcohol 
(in litres) per year (presented in Figure 2-4) for the years of 2005 and 2008 was 4.4 and 6.04, 
respectively. The Figure 2-4 also shows that alcohol consumption has increased between 2005 
and 2008 in all regions. The Europe region (EUR) had the highest level of alcohol 




had a stable level of alcohol consumption in the last decade. Studies indicate high level of 
alcohol consumption in eastern European countries, and low level of alcohol consumption in 
Nordic countries (Popova et al., 2007). 
Figure 2-4: Total adults (15+ years) per capita consumption of pure alcohol (in litres) 
 
The high level of alcohol consumption in EUR is also apparent from Figure 2-3 of OECD 
health data where the majority of these countries are in EUR. The alcohol consumption is 
lowest in the Eastern Mediterranean Region (EMR), where the majority of the population are 
Muslim (GreenFacts, 2006b). However, according to WHO (2011b) EMR has 56.2% of 
homemade and illegally produced alcohol beverages of APC in 2005. This figure is the 
second highest next to South-East Asia which has 69.0% of illegally alcohol beverage 
production. The homemade and illegally produced alcohol beverages could be fatal and can 
cause acute death as well as disability (GreenFacts, 2006b). 
 
2.3 Literature Review  
2.3.1 Consequences of Alcohol Consumption  
Alcohol consumption has adverse consequences to those who consume, people around those 
who drink and as well the nations whose people drink more. These consequences can be 
classified as health, economic, and social consequences. Studies indicate different numbers as 

































AFR AMR EMR EUR Global SEAR WPR
AFR=Africa; AMR=Americas; EMR=Eastern Mediterranean; EUR=Europe; SEAR=South-East Asia; WPR=Western Pacific; Global
Source: (WHO, 2011a)
2005 2008**





condition (Room et al., 2005) to more than 200 different diagnostic heath problems (WHO, 
2011b)  to be causally linked to alcohol consumption directly or indirectly; more than 30 of 
these medical problems are indicated to be either directly caused by alcohol use or alcohol is a 
necessary risk factor for the causations of these illnesses (WHO, 2011b). Alcohol use 
disorder; breast cancer; cerebrovascular disease; colon and rectum cancers; diabetes mellitus; 
drownings; falls; fires; ischaemic heart disease; liver cancer; liver cirrhosis; mouth and 
oropharynx cancer; oesophagus cancer; poisoning; prematurity and low birth rate; road traffic 
accidents; self-inflicted injury; other unintentional injuries; violence are among the most 
common known problems which are in one-way or another related to alcohol consumption.   
The health consequence of alcohol is usually expressed both in terms of mortality and 
disability adjusted life years (DALYs). DALYs is a method of measuring the number of 
health years lost and ranges from 0 (perfect health) to 1 (death); it is a method of weighting 
the value of a lifetime with a certain disease (Arnesen and Nord, 1999). DALYs, first 
developed by the World Bank, is widely applied in health literature and policies as an 
important health care indicator (Lyttkens, 2003). The disability and morbidity burden of 
alcohol is more extensive than that of mortality (Rehm et al., 2003a).  In this section the 
alcohol-attributable mortality and DALYs in Norway and the globe are briefly explained. 
2.3.1.1 Alcohol-attributable Burden of Disease in Norway 
There is little literature available about the burden of alcohol related diseases in Norway. 
However, according to the WHO statistics database, as the consumption level of alcohol in 
Norway is low so is its burden of diseases. Yet contrary to the increasing but stable level of 
alcohol consumption in Norway as shown in figure 2.2, the alcohol-related mortality for both 
men and women has been decreasing with little fluctuation for men. The alcohol-related 
disease mortality in Norway from 2002 to 2007 is shown in Figure 2-5 below. Alcohol-
attributable disease mortality for 19 countries including Norway can be seen in appendix 
A.VII- Table 8-9. While the mortality attributable to alcohol was higher for male, it was low 
for both genders during this period. Less than 15 men per 100,000 died for alcohol-
attributable diseases, whereas the figures are much lower for women, which are less than 5 




Figure 2-5: Alcohol-related disease mortality in Norway, 2002-20071 
 
A little more detailed summary of the major causes of the alcohol-attributable burden of 
disease in Norway in 2004 both in terms of DALYs and Mortality is presented in appendix 
A.VII-Table 8-10. As the table 8.10 indicates the proportion of the burden differs between the 
19 specific diagnoses as well as between men and women.  Alcohol use disorder, Ischaemic 
heart disease and Cerebrovascular account for the highest burden with 969, 482 and 283 
DALYs per 100,000 respectively for both genders. But the burden is higher for men than 
women in all these three cases with 1497, 725 and 316 DALYs per 100,000 respectively for 
men as compared 425, 254 and 253 DALYs per 100,000 respectively for women. With 
exception of breast cancer, and Prematurity and low birth rate, the alcohol-attributable 
DALYs are higher for men than women for the all diagnoses listed in table 8.10. Similarly, 
the Ischaemic heart disease and Cerebrovascular account the highest alcohol-attributable 
deaths with 72.7 and 37.3 deaths per 100,000 for both men and women respectively, the 
mortality attributable to alcohol is also higher for men than women with exception of the 
breast cancer only. 
 
2.3.1.2 Alcohol as a Global Health Problem 
There are widespread health, economic, and social problems associated to alcohol 
consumption throughout the world. Rutherford andMcNeill (2009) termed these problems as a 
worldwide epidemic harm resulted from high global consumption of this commodity. 
According to Greenfacts (2006a) the average volume of alcohol consumption is about five 
                                                          
1
 WHO estimates using Single, E., D. Collins, B. Easton, H. Harwood, H. Lapsley, P. Kopp and E. Wilson (2003). International Guidelines 







































liters per person per year. It differs from region to region with highest alcohol consumption in 
Europe, as shown in figure 2-4. The alcohol-attributable deaths and disability is also highest 
in Europe, however, there is no region which is not affected by the alcohol harms (Rehm et 
al., 2009). According to WHO (2011b) around 2.5 million lives lost their live due to unsafe 
use of alcohol. Rehm et al. (2009) indicates that 3.8% of the total mortality and about 4.6% of 
the DALYS are associated with alcohol use. According to Rehm et al. (2009) the mortality 
and morbidity related to alcohol is higher for males than for females in all regions. The reason 
could be because, as Wilsnack et al. (2009) indicates, the average alcohol consumption of 
males is higher than that of females.  In 2011 among the major risk factors causing death and 
DALYs globally was alcohol, which accounted 8
th
 in mortality and 3
rd
 in terms of morbidity 
(WHO, 2011b). Alcohol consumption victimizes not only by alcohol consumers but also non-
alcohol users as it endangers the lives of those around when misused (Friedman and Klatsky, 
1993). Premature and low birth weight for newly born children, accidents, violence, 
intentional and unintentional harms to other people are the common risks for other people 
(WHO, 2012). This clearly depicts how hazardous medical conditions associated with alcohol 
consumption, are in the global arena.  




























































































































































































































While the toxicity of alcohol consumption varies with the amount consumed (WHO, 1994), 
yet there is strong counter argument whether moderate drinking is safe and good for the health 
(Ashley et al., 1994; Melberg, 2006). Irrespective of moderate or heavy drinking habits, the 
harmfulness of this commodity is becoming more and more apparent. Control measures are 
demanded to reduce the risks of alcohol to the millions of lives throughout the world every 
year (Rutherford and McNeill, 2009). Accident involving alcohol consumption, which is one 
the main diagnoses entirely attributable to alcohol, results in high mortalities and morbidities 
throughout the globe. The road traffic fatalities involving alcohol drinking for 32 countries in 
2005 is presented in figure 2.6 above. The figure is constructed from the estimated road traffic 
fatalities in appendix-A.VII, Table 8-8.  Half of all these countries experienced more than 
20% of all road traffic fatalities due to alcohol drinking in 2005. Norway is among these 
countries. According to Gjerde et al. (1993) 28% of injured drivers by car accidents in 1989 
and 1990 were related to alcohol use; recent studies indicate high traffic incidents associated 
to alcohol (Gjerde et al., 2011). The figure 2.6 shows great variation between these countries; 
such kind of variation could be a result of alcohol drinking habits or other country specific 
factors.   
Figure 2-7: Regional variations in proportion of alcohol-attributable deaths and DALYs in Europe, 2004 
 
 
Figure 2.7 provides a picture of the proportion of alcohol-attributable deaths and DALYs in 
five European regions; shows high alcohol-attributable DALYs in the Nordic countries (NC), 
however, according to WHO (2012) this could be because of the longer life expectancy with 
disability in this region when compared the other four regions. As the figure 2.7 shows the 






























































mortality and DALYs. According to Popova et al. (2007) the high alcohol-attributable burden 
of disease in CEEEU is associated with the high consumption of alcohol in this region when 
compared to other parts of Europe.  
 
2.3.2 The Economic Burden of Alcohol Consumption 
 
Health care spending as a share of the GDP in all OECD countries was increasing for the past 
half century. And although the Norwegian health care spending as a share of its GDP is not 
that much higher than the average OECD countries’ spending; the adjusted health care per 
capita spending shows otherwise which is, extremely high. In the later case, Norway is the 
second highest next to United States (OECD, 2009; OECD, 2011a).  
 
The increasing health care expenditure are due to, among other things, the good living 
standard of the individuals, the high life expectancy which increased the aging population, 
and the innovation and using new advanced technology, treatments and procedures in medical 
sector (Jones, 2004). However, there no debate that the rises of chronic illness have a huge 
contribution to the increasing health care costs.  Finding different health care cost drivers are 
essential for future cost control and prevention.  
 
The cost of alcohol related diagnosis is no exception since as mentioned above many of these 
chronic diseases are attributed to consequences of alcohol use. Whether the health and social 
consequences are causally attributable to alcohol consumption or whether the general 
condition of treatment methods of the diagnoses are affected by indirectly by alcohol 
consumption; whole or fractions of the economic losses due to these health consequences are 
to be regarded as alcohol-caused losses. These losses are what constitute the economic burden 




Table 2-1: The Overall comparison societal cost burden of alcohol 
  
Source: Adapted From Baumberg (2006) 
 
In 2002 the cost of alcohol consumption was estimated between $210 – 665 billion globally 
(Baumberg, 2006). According to Rehm et al. (2009) both high and middle-income countries 
spend 1% their gross national product (GNP) due to the detrimental effects of alcohol 
consumption. In Norway NOK 18 – 19 billion were estimated to the economic cost of alcohol 
burden (Gjelsvik, 2004); in 2003the total tangible cost of alcohol accounts for about 1.2% - 
2.1% of GDP as shown in table 2.1 above  (Baumberg, 2006). WHO database for the 
economic burden of alcohol shows substantial social costs of alcohol; in 2000 more than $200 
billion losses were attributed to alcohol in United State of America (USA). Half of these costs 
were indirect costs. Germany (in 2007) and United Kingdom (in 2003) lost more than $30 
billion due to alcohol use (WHO, 2011a). The table 2.1 above gives a picture of economic and 









3.  Theories  
3.1 Theories of Alcohol Use 
In almost all social perspective towards the negative effect of alcohol, the dependency 
problem is apparent, however, according to some studies, low and moderate consumption of 
alcohol is more beneficial to health rather than harming (Ashley et al., 1994; Ashley et al., 
1997; Doll, 1998). These conceived beliefs could be the reason why most of the theories of 
alcohol consumption address the substance misuse, which confines to theories of alcohol to 
the problem of dependency. In other words they focus on problems related to alcohol misuse 
rather than alcohol use. Moreover, the theories of alcoholism are divided over the issue of 
alcohol abuse whether it is habit or a disease (Korhonen, 2004). One of the mainly applied 
theories to alcohol use is the behavioral theory, it is widely applied to college students’ and 
adolescences’ alcohols misuse. It is a very wide concept of theory applied as individual, 
social, economic, and sometime parental behavior. It is a broad concept and cannot be 
explained in depth in this study. Those interested to know more about behavioral theory of 
economics can refer the editorial article of Bickel et al. (1995). In this section it is briefly 
pointed out the behavioral economics. The intention of the behavioral theory of addiction or 
misuse of alcohol should not be misunderstood here; it is not to generalize to the overall 
drinking habits; but to enlighten how some of the most well known alcohol problems arise.  
Economists are divided over how to apply the behavioral theory to alcohol dependency. There 
are those who argue that addiction to alcohol for example, is an economically rational 
behavior that individuals make just as they do in other normal goods (Tomer, 2001). They 
base their arguments to Gary Becker’s rational theory of addiction, who argued in the late 
1980s that addiction is consistent to the rational theory of maximizing utility (Becker and 
Murphy, 1988). Becker andMurphy (1988) explained how addiction is simply a means of 
trying to reach a stable point, but the current consumptions’ negative effect to the future 
consumptions’ utility increases the consumption of the addictive good in the future; which is 
as they argued normal behavior. They also tried to justify their theories by indicating how 
addiction behavior applies to wide varied normal goods. Bask andMelkersson (2004) argue 
that alcohol addiction in particular is consistent to rational behavioral theories of economics. 
However, Tomer (2001) explained by using psychological and physiological point of view 
that addiction is not rational behavior. For an individual to make a rational choice, he/she has 
to have control over his/her choices both pre and post consumption of the addictive good. 




cause the individual to over consume the addictive good at the first place (Tomer, 2001; 
Korhonen, 2004). This leads to addiction which later on his/her lifetime takes control of the 
individual decision making process regarding to the amount alcohol consumed (Tomer, 
2001). 
The point here is not whether an addiction is rational or not, but the pattern that leads 
individuals to consumes more of a toxic substance like alcohol. While both arguments explain 
how addiction develops, later argument of Tomer (2001) is more applicable in real life, 
because it takes into consideration the external factors which influences pre and post 
addiction. By acknowledging the harmfulness of the addictive commodity, Tomer (2001) 
incorporates  the habit point of view of alcoholism to that of the disease point of view. 
3.2 Alcohol-attributable Fractions (AAF) 
It was explained in the previous sections how wide and complex is the burden attributable to 
alcohol consumption throughout the globe in terms of economic, social and health 
consequences. How to estimate these consequences are the main challenges faced by many of 
the studies conducted about this area, because of the multiple risk factors involving same 
health problem. The majority of the health consequences related to alcohol are partially 
attributable to alcohol consumption, so it would be misleading if the whole consequences of 
these partially related disease recorded as alcohol-related burden. In Epidemiology it is very 
important to quantify the fraction of the burden of a disease that is related to a particular risk 
factor (Laaksonen et al., 2010). The mainly used method of quantification is the population 
attributable fraction (PAF) which assigns the proportion of the risk to the multiple risk factors 
found to have causal link to the occurrence of a particular health problem in a given 
population (Laaksonen et al., 2010). The PAF is commonly defined as a means to differentiate 
the occurrence of the disease between those exposed to the risk factor and those not exposed 
in same population (Jones et al., 2009). PAF is superior to other epidemiological measures 
like relative risk and odds ratio, because it considers both the prevalence of the risk factor and 
the strength of the causation between the risk factor and the health outcome (Laaksonen et al., 
2010). Since its introduction in 1953 by Levin in his study of the occurrence of lung cancer in 
man (Rockhill et al., 1998) PAF has been used and applied to very wide and varied health 
conditions (Laaksonen et al., 2010). Alcohol-attributable fraction (AAF) is one of the PAFs, 
which is applied to alcohol as risk factor to many chronic and acute health conditions. It 
specifically measures the proportion of health consequences that is attributable to alcohol 




health consequence that is positively related to alcohol drinking (Jones et al., 2009). In other 
words, it estimates that proportion of diseases mortality and morbidity that would not have 
existed had it not been alcohol consumption (Taylor et al., 2011). AAF makes the 
quantification easier and closer to accuracy and thereby helps to introduce appropriate policy 
intervention.  
The relative risk of specific disease could differ between male and female; it could also differs 
among the age-groups of same gender (Eshima et al., 2012), because of this reasons, different 
AAF is applied to men and women, and to different age-groups. This method of quantifying 
alcohol risk fraction is conducted in many countries worldwide. When the term alcohol-
attributable fraction is searched in PubMed database 186 results were found (Searched date: 
04 August, 2012).   Among them are (Rehm et al., 2006; Taylor et al., 2011) conducted in 
Canada, (Cherpitel and Ye, 2008) in US. 
 
3.3 Economic and Societal Cost Studies of Alcohol 
Consumption  
 
As mentioned in the introduction, numerous evaluations for the consequences linked to 
alcohol are conducted regularly. The convoluted and indistinguishable multidimensional 
relationship between the alcohol consumption and related health problems (Rehm et al., 2010) 
make vital for such continuous evaluation of alcohol consequences. As the health 
consequence of alcohol affects not only to the drinkers but also the whole individuals 
surrounding to them like family members and friends, so is its economic consequence 
(Navarro et al., 2011). The social and economic costs of alcohol are wide and affect the whole 
economy. It is not a surprise that one of the focal and well-known among alcohol related 
studies is the economic evaluation, which explores the economic burden of alcohol 
consumption to the society.  
These kinds of economic evaluations examine different perspectives, broadly the linkage 
between the cost burden of alcohol and its consequences, and the costs of the alternative 
treatment options for the alcohol related diseases and treatment outcomes. Drummond et al. 
(2005) defined the economic evaluation ‘as the comparative analysis of alternative courses of 




compare the costs and consequences...’. It is a widely applied method in health economics. 
French (2000) listed more than 30 studies of economic evaluation of alcohol treatment 
services since 1983. Many more studies were conducted since French published his study. 
Baumberg (2006) included 30 alcohol cost studies in his study of global economic burden of 
alcohol since 1990. Table 2.1 adapted from Baumberg (2006)can be seen the societal cost of 
alcohol from different countries. Same applies to other economic evaluation perspectives 
related to alcohol. 
There are increased various uses of the findings of these studies like decision making on 
prevention, reduction of alcohol consumption or cost minimization of the treatment options of 
alcohol-related illnesses (Thavorncharoensap et al., 2009). There are three main methods of 
economic evaluation for comparing costs and consequences; namely cost-benefit analysis, 
cost-effectiveness analysis (CEA) and cost utility analysis (Drummond et al., 2005). This kind 
of classification is not important for this study, however, what most, if not all economic 
evaluations have in common is the inclusion of the indirect costs and opportunity cost.  
3.3.1 Cost Inclusion of the Economic Burden of Alcohol  
There are many cost items included for the economic burden of alcohol as its consequences. 
Some of the most commonly considered cost items of alcohol are presented in the figure 3.1 
below. The largest cost components of alcohol are health care costs, social services, crime, 
and research, policy and prevention (Jarl et al., 2008). Detailed explanation of these 
components are not important here, however, the important point is to recognize that health 
care costs includes not only the attributable fraction of alcohol-related diagnoses but also 
fractions of costs of some non-alcohol-related diagnoses which is believed that alcohol has 
impact on the effectiveness of the treatment methods and recovering process (Johansson et al., 
2006).  
Does alcohol have some effects on the treatment process on causally non-alcohol-related 
diagnoses? Are all diagnoses with unknown alcohol-association that somehow alcohol affects 
their treatment being considered in economic evaluation of alcohol costs? If not so, which are 
the most probably ones, how big and significant are these costs? These questions and other 
related ones are the main focus of this study. The complex association between alcohol 
consumption and its harmful consequences mentioned before made ambiguous as to what cost 
items be considered and there are wide differences among the respective literatures (IAS, 




The burden of alcohol affects the whole economy and almost every sector. The productivity 
loss due to alcohol use is a widespread loss which directly or indirectly involved many 
sectors. But the complexity involving such losses makes always impossible to capture the true 
productivity loss. However, as Thavorncharoensap et al. (2009) indicated there is high 
percentage of alcohol-related costs which indirect costs; and the productivity losses of the 
other sectors are recorded as indirect costs. 
Figure 3-1 Cost Items of Alcohol Consumption 
 
Alcohol prevention policy become a global campaign, the economic evaluation studies 
described above are used the main engine for developing and implementation of appropriate 
policy towards reduction of alcohol consumption. Reduction of alcohol consumption was 
found to have substantial economic benefit; which results from lower mortality and 
morbidity, reduction of health care expenditure and productivity loss as the incidence of 






3.4 Co-morbidity and Multi-morbidity 
 
Co-morbidity is defined into different ways in different literatures; it is sometimes used 
interchangeably as multi-morbidity, patient complexity and other terms (Safford et al., 2007; 
Valderas et al., 2009). It is commonly referred as either the coexistence of several diagnoses 
together or additional diagnoses to an index diagnosis (van den Akker et al., 1996; Fortin et 
al., 2005). Either way the implication is that patient has several diseases (diagnoses), which 
are occurring at a same time span. This does not mean that diseases occurring starts and ends 
at same specific time, but it means that during a period a patient had a disease; other diseases 
also occur to the same patients before he/she recovered from the previous disease. 
 In epidemiology, co-morbidity was always a problem, the clinical attention improved from 
the last two decades (van den Akker et al., 1996) as compared to four or five decades ago 
(Feinstein, 1970). Co-morbidity of the chronic diseases is more usual and it is higher for the 
elderly population (van den Akker et al., 1996; Gijsen et al., 2001). While co-morbidity does 
not usually mean that these diseases cause one another (Hall et al., 2001), yet it is a burden to 
the patient as it increases the vulnerability of the patient and the likelihood of dying due to an 
index diagnosis (Gijsen et al., 2001). It lowers the health quality of life; and moreover, it 
affects the recovering process of the patients from an index disease by complicating the 
diagnostic and treatment procedures; which in turn increases the cost of treating a patient 
from an index disease (Fortin et al., 2007a; Fortin et al., 2007b; Valderas et al., 2009). 
In this paper, the concept of co-morbidity is used to imply the coexistence of alcohol-related 
diseases with other non-alcohol-related disease. The index diseases are the non-alcohol-
related diseases and the effect of alcohol-related diseases on treatment costs for these index 
diagnoses is the main focus of this paper. While the co-morbidity is a universal problem to all 
diagnoses, whether diseases are alcohol-related or not, how to manage the economic loss due 
to the co-occurrence of diseases is an important question. Problems of estimating the clinical 
burden of co-morbidity (Fortin et al., 2005), could also be an obstacle to quantify the 







4.  Study Design and Methodology  
4.1 Conceptual Framework  
 
There are many different types of alcohol. The term alcohol as meant here is the alcohol 
people consume as beverages like wine, beer and spirits. This definition is consistent with the 
definition used by the international handbook on alcohol and culture (Heath, 1995). The 
limited availability of data in this study, constrains a better way of classifying patients into 
alcoholic and non-alcoholic; or into heavy drinker and moderate drinker. However, since with 
high consumption of alcohol the risk of alcohol-attributable diseases increase (Bentzen and 
Smith, 2011), it was assumed that all patients above 18 years with alcohol-related diagnoses 
were alcoholic. Those patients without alcohol-related diagnoses were assumed to be non-
alcoholic. Here non-alcoholic was not meant abstainers, since there could be some patients 
who in reality drink, but did not show symptoms of the diseases related to alcohol yet. Neither 
was alcoholic meant heavy drinkers, as moderate drinkers could have alcohol-related diseases. 
So the terms alcoholic and non-alcoholic were used here just to distinguish those with alcohol 
co-morbidities from those without these co-morbidities. The figure 4.1 below illustrates the 
general conceptual framework of this study.  
Figure 4-1: Conceptual framework of the study 
 
As mentioned in the background section, the relationship between diseases and alcohol 
consumption is very complex. The multi-causality of diseases also makes it more difficult to 
capture the true consequences attributable to alcohol. A method of estimation for the 
consequences (loss) of alcohol was developed for those diseases with known alcohol 




previous section. Economic evaluation of alcohol bases their estimation of economic loss of 
alcohol consumption by AAF. It is these economic evaluations and analyses which are later 
used for the development of preventive and reduction policies.  
There are many other diagnoses, which the relationship with alcohol is unknown. The 
question is whether the treatment of patients who were diagnosed with alcohol-related health 
problems is more costly than other patient. If this is the case, then it means non-alcohol-
related diagnoses which are more costly because of alcohol consumption (alcohol 
comorbidities) have to be included in economic evaluations by developing and estimating the 
fraction which is attributable to alcohol. By including such costs, if any, would lead to a 
reduction in the underestimation of economic burden of alcohol, and hence more effective 
control and preventive policies of alcohol consumption.  
While environmental and geographical factors complicate the development of cost estimation 
for such diagnoses, continuous researches and developments in this area are always feasible 
and are essential for achieving it. The empirical analysis of cost and cost comparison between 
alcoholic (those with alcohol co-morbidities) and non-alcoholic (those without alcohol co-
morbidity) of this study is expected to contribute.  
4.2 Data Collection  
 
The study was based on a dataset of Norwegian Patient Registry (NPR) in 2008. The 
Department of Health Management and Health Economics at University of Oslo originally 
received the data for other studies. The data initially contained more than 1 million 
observations of which more than 400,000 observations were not eligible and excluded due to 
age limit of 18 – 79 years. The registry had more than 7000 specific diagnostic conditions 
based on International Statistical Classification of Diseases and Related Health Problems 10th 
Revision (ICD-10). Length of hospital stay (LOS), demographic features, and costs incurred 
for each specific treatment estimated based on DRGs system estimation were included in the 
data. The NPR collects patient records from both public and private hospitals (Bakken et al., 
2012). However, since the Norwegian health care system is dominated by the publicly owned 
health institutions (EUOHCs, 2000), the records of the dataset were mostly from public.  
The data had patients with multiple observations, so the structure of the data was longitudinal 




2008. In order to fit the data for the applicability of the appropriate statistical models 
explained in the model section (4.7) of this chapter; the data was reshaped by collapsing it in a 
long format for identical specific diagnosis at different hospital admissions during the year of 
2008.    
4.3 Grouping and Selection Criteria 
 
In order to examine whether alcohol indirectly effects on the treatment process of non-
alcohol-related diagnoses (diagnoses not yet discovered to be associated with alcohol 
consumption, or diagnoses which are not usually included in alcohol cost estimation), the data 
observations were classified into two groups. The alcoholic group that was the group of 
interest and a control group which contained patients who were not diagnosed with alcohol-
related diseases. It was noted with the difficulties and complexity involving on how to group 
patients without any record of drinking habits available in the dataset. However, a selection 
criterion was developed based on diagnostic records of patients. Patients diagnosed with 
diseases that are either fully (Appendix-A.I-Table 8.3) or partially (Appendix-A.I -Table 8.4) 
attributable to alcohol were included in the alcoholic group.  The rest of patients were 
considered to be non-alcoholic. It is important to remember the meaning of alcoholic and non-
alcoholic as it was described in the conceptual framework (4.1). The ICD-10 classification 
codes were used as a tool for selection process. 
4.3.1 Diagnoses Selection 
 
The diagnoses of interest were not the alcohol-related diagnoses but instead the unrelated 
diagnoses, the diagnoses that were common to both alcoholic and non-alcoholic groups. 
Based on these criteria more than 350,000 observations of non-alcoholic group and around 
90,000 alcoholic group have been diagnosed to more than 6000 specific diagnostic health 
conditions which were not related to alcohol and/or is not included to economic evaluations of 
alcohol.  
All the diagnoses, which studies indicated association with alcohol consumption like 
malignant neoplasms (Cargiulo, 2007); intestinal infectious diseases (Cook, 1998); nutritional 
anaemias (Ioannou et al., 2004); diseases of the eye and adnexa (Kaimbo et al., 2001); 
inflammatory polyarthropathies (Jaakkola and Gissler, 2005); and Renal failures (Perneger et 




related to alcohol. Other follow up diagnostic procedures were also excluded as there was 
little information about the diagnoses followed up. Still there were many specific diagnoses 
included in the data registry. However, most the diagnoses had very small observations, and it 
was not possible to compare the two groups. Further selection process was conducted based 
on sample sizes of all these specific diagnoses. 
In order to exclude those diagnoses with fewer observations in either of the two groups, a 
criterion of at least 100 observations per group was set before collapsing dataset. Finally a 
total number of 21,105 observations (table 4.1): 18,203 control groups and 2,902 alcoholic 
groups for 8 specific diagnoses were selected and applied in the analysis. As the table 4.1 
below shows, the frequency distribution of gender with respective group-category and 
diagnoses was not that much different between women and men. The 8 diagnoses listed in 
table 4.1 were selected for two main reasons. First these diagnoses were not included in the 
literature of economic evaluation of alcohol (because there are no known association between 
alcohol and these diagnoses), and second these diagnoses had the maximum comparable 
observations when compared to other diagnoses. The 8 diagnoses are: -  
Erysipelas (A46) is a skin infection caused by streptococci. While it could be cured with 
simple treatment methods like antibiotics, erysipelas is a serious infection which can lead to 
potential harmful situation if not controlled properly (Eriksson et al., 1996; Dupuy et al., 
1999). Although it affects the legs, yet hospital admission to the patients affected is common, 
which creates debates about the cost issue (Eriksson et al., 1996; Dupuy et al., 1999). While 
some studies consider alcohol misuse as risk factor for the Erysipelas (Dupuy et al., 1999), its 
costs of treatment are hardly considered when estimating the economic and societal cost of 
alcohol.   
Volume depletion (E86) also called as extracellular fluid depletion is a condition which body 
cells loss both water and sodium salt fluids (Spital, 2007; Bhave and Neilson, 2011). Volume 
depletion is different from dehydration pathophysiologically as well as the treatment 
procedure required (Spital, 2007; Bhave and Neilson, 2011), but it is similar to dehydration. It 
causes low blood volume circulation (Bhave and Neilson, 2011). There are no available 
studies which could link alcohol as a risk factor for volume depletion. 
Unspecified asthma (J459): Asthma is a potential risk condition for both children and adults 
which results mostly in morbidity and sometimes death. Enormous medical resources are used 




asthma (Sears, 1997; Lugogo and Kraft, 2006). The risk factors and causes of asthma are very 
complex, and there are many things that are not known yet, however genetic and 
environmental factors are usually associated with the cause of asthma (Lugogo and Kraft, 
2006). In ICD-10 codes there is a diagnostic asthma condition (J459), which is unspecified; as 
the name indicates it is not known what kind of asthma it is or what causes it. 
Acute tubulo-interstitial nephritis (ATIN- N10) is an inflammatory disease which patient 
gets high blood urea nitrogen (Ulinski et al., 2012). It is associated to early acute renal failure, 
several drugs including Non-steroidal anti-inflammatory drugs (NSAIDs), infections, and 
toxins (Vanhaesebrouck et al., 1985; Rocha and Fernández-Alonso, 2001; Ulinski et al., 
2012). It could impair the proper function of the kidneys because 95% of the kidney contains 
interstitium and tubules (Ulinski et al., 2012); therefore patients are usually hospitalized to 
avoid the risk associated with this diagnoses.  
 
Unspecified Chest pain (R074) is a non-cardiac chest pain which is not known the underlying 
cause (Eslick, 2008). A chest pain, usually treated at the primary health care, occurs to a large 
number of people of all ages (Eslick et al., 2003; Ruigomez et al., 2006; Eslick, 2008). There 
are multiple risk factors for chest pain, among the commonly associated ones are 
gastrointestinal, cardiac, musculoskeletal, psychological, family history, neuroticism, 
dysphagia, malignant and pulmonary diseases (Ruigomez et al., 2006; Eslick, 2008). The 
unspecified chest pain, though not known what causes, can result in detrimental effect on the 
health and endanger the life of the individuals (Ruigomez et al., 2006). Patients are commonly 
admitted in hospital emergency but also hospitalized for this diagnosis.  
 
Pain localized to upper abdomen (R101) Abdominal pain is horrid abdominal tenderness 
which can be chronic or acute health condition. It involves tissue injury influenced by both 
path-physiological and psychosocial factors (Glasgow and Mulvihill, 2002). While it is not 
always the case, abdominal pain could cause death (Flasar and Goldberg, 2006); and it is a 
very complex diagnosis which is sometimes treated as inpatient. One of the specific diagnoses 
related to abdominal pain is the one localized to the upper abdomen.  
Unspecified fever (R509) is a high temperature of patients with unknown cause (Bodenreider, 
2001). A patient is said to have fever if his/her body temperature is greater than 38°C. It is 
usually a reaction of body for some underlying infections (Kluger et al., 1998). While fever is 




destroy tissues and body cells, but can also kill patients (Dubois, 1949). Besides the unknown 
factors causing the fever can impair the health quality of the individual if not given proper 
action. So patients are hospitalized for unspecified fever. 
Other and unspecified convulsions (R568) – Convulsion is a complex chronic health 
conditions which needs to be monitored with its simple seizure, epilepsy or other convulsive 
disorder. There are cases which is ambiguous as to what kind of convulsion it is, these kinds 
of convulsions, which are not epilepsy, are called unspecified convulsion in ICD-10 (Jetté et 
al., 2010). 
4.4 Problems and Data Limitations  
 
The registry data lacked individual specific characteristics like history, lifestyle (smoking, 
exercise…etc) and more importantly the drinking and other diet habits of the individuals. 
These missing factors would help not only to distinguish the alcohol consumers from non-
alcohol consumers, but also could have been used as control variables to capture the pure 
effect of alcohol consumption to the treatment cost and LOS. These factors were assumed to 
be random and equal to all individuals, and therefore it accounted the biggest limitation of this 
study. It limited the generalizability of the findings of this study. Moreover, as many 
retrospective observational data are subjected to errors of measurement, so was this study. A 
measurement error in this study could be misdiagnosis of the patients which is a common 
error in diagnostic procedures.  
Moreover, the selection criteria for identifying the observations into alcoholic and non-
alcoholic could lead selection bias, as there is no record of alcohol drinking in the dataset. For 
example, there is a possibility to have a disease partially attributable to alcohol although the 
individual was in fact abstainer. If this happens, it means such kind of individual was 
identified as an alcoholic. While it is important to take these limitations into consideration 
when interpreting the results, the findings of this study could still be used to reevaluate the 






4.5 Data and Variable Description  
4.5.1 Data Description  
The sample size and frequency distribution of the two groups is presented in table 4.1 below. 
As the table indicates the frequency distributions of the two groups were different. The total 
sample size of the alcohol group was only 2,902 observations, which is less than 15% of the 
total observation of the study (21,105 patients). Unbalanced sample size are common on 
retrospective observational studies. 
Table 4-1: Sample Size and frequency distribution by gender 
 Women Men Both Total 
Diag  Non-alcohol Alcohol Non-alcohol Alcohol Non-alcohol Alcohol  
A46 850 96 1470 159 2320 255 2575 
E86 235 110 164 87 399 197 596 
J459 423 60 204 31 627 91 718 
N10 1159 127 465 107 1624 234 1858 
R074 5071 724 5914 955 10985 1679 12664 
R101 618 94 408 88 1026 182 1208 
R509 181 52 199 46 380 98 478 
R568 352 62 490 104 842 166 1008 
Total 8889 1325 9314 1577 18203 2902 21,105 
A46 – Erysipelas; E86 – Volume depletion; J459 – Asthma, unspecified; N10 – Acute tubulo-interstitial nephritis; R074 – Chest pain, 
unspecified; R101 – Pain  localized to upper abdomen; R509 – Fever, unspecified; R568 – Other  and unspecified convulsions 
The cell variations of the two groups became even wider as the observations of the data were 
categorized based on the 8 specific health conditions.  As presented in last three columns of 
the table 4.1 above, the sample size difference between the two groups in most of these 
diagnostic categories was very wide. The problem of unequal cell size between the two 
groups usually creates heterogeneity of variance between the two groups. While this was a 
limitation of the data distribution, it was taken under consideration when developing an 
appropriate statistical model by assuming heterogeneous variance when suspected (refer to 
section 4.7).  The health conditions listed in the table are disease specific diagnoses, which are 
very precise health conditions. 
4.5.2 Variables Description  
The main variables of interest were the treatment cost, the length of stay (duration of hospital 




gender, which were used to control individual specific character.  As mentioned in the 
previous sections the main objective of the study was to find out whether LOS and cost 
differed between the alcoholic group and the non-alcoholic group. Both variables were 
included in the descriptive statistics as well as in the main results analysis. In descriptive 
statistics mean and standard deviation were used for both variables. However, in results 
analysis two different models (section 4.7) were applied to LOS and cost, mainly because of 
the varied nature of the two variables.  
Table 4-2: Type and nature of variables 
variables type nature categories unit of 
measurement 
Cost Dependent  continues - Norwegian kroner 
Length of stay (LOS) Dependent continues  - days 
alcohol factor explanatory  category 2  groups Non-alcoholic ‘0’ 
Alcoholic ‘1’ 
Gender control  category 2 groups Female ‘2’ 
Male ‘1’ 
Age control  category 2 groups 18-49 ‘0’ 
50-79 ‘1’ 
 
The private costs and production loss were not included, which means the cost estimation was 
purely institutional cost, not societal cost. The unit of measurement for cost variable was 
Norwegian Kroner value of 2008. The variable LOS was a discrete count variable (LOSi = 0 1 
2 3… n), which was the total number of days patients hospitalized for specific diagnosis 
during 2008. The alcohol factor (variable) was a categorical dummy variable of two groups, 
that was the alcoholic group coded as “1” and the non alcoholic group as “0”. This variable 
was the main explanatory variable intended to measure. The drinking habit of individuals was 
not available; therefore, individuals were categorized based on diagnoses related to alcohol 
(see section 4.3). Other variables like gender and age were also included in the explanatory 
variable to find any effects that these factors might had on the result. Both of these factors 
were also categorical variables. The gender was as usual two categorical groups where “1” is 
coded for male and “2” for female, a dummy variable was not created for this variable, 
because models were applied separately for male and female observations. The objective was 
to clearly capture the effect of alcohol factor on treatment, so in this case same gender 
observations but different groups (Alcohol factor) were compared. In appendix A.I, the 
gender effect is presented and male was taken as a reference group.  The third explanatory 




other for regression models. In the descriptive statistics, age was grouped into seven 
categories. However, age was grouped into two categories (i.e. 18 – 49 coded as “0”; and 50 – 
79 coded as “1”) in regression analysis due to reasons related to cell size. 
4.6 Descriptive Statistics 
The simple descriptive statistics cannot be used to conclude significant variations between the 
two groups. However, the descriptive statistics help to explore and easily discover whether 
there are variations between and among groups. Table 4.3, Table 4.4, Table 5.1, Table5.2, and 
Figure 4.2 – Figure 4.5 provide simple descriptive statistics of hospital treatment cost and 
length of stay (LOS). The mean and standard deviations of both LOS and hospital treatment 
cost by alcohol group (diagnoses with alcohol related diseases or not) and gender are 
displayed in table 4.3 below. The mean difference between and among groups is presented in 
table 4.4. Figure 4.2, figure 4.3, figure 4.4 and figure 4.5, supplement the information given in 
Table 4.3 and Table 4.4. In these figures the age factor is included, and therefore more 
information is provided in these figures by comparing the cost and LOS of the alcoholic and 
to that of the non-alcoholic by gender and age.  
As the table 4.3 indicates the alcoholic group (patients with alcohol related diseases) had 
higher hospital treatment costs and longer LOS than control group (patients without alcohol-
related diagnoses) for all 8 specific diseases except the unspecified fever (R509). The non-
alcoholic had 0.15 longer LOS than the alcoholic group for the unspecified fever as shown in 
table 4.3 and table 4.4.  The mean differences can be easily observed in table 4.4 below. 
4.6.1 Descriptive Statistics for Hospital Treatment Cost 
The cost variation between alcoholic group and non-alcoholic group is wider in the 
unspecified Asthma (J459) diagnosis. The alcoholic group had NOK 21745.4 more cost than 
the non-alcoholic group for the treatment of unspecified asthma. The unspecified chest pain 
(R074) diagnosis had the smallest cost variation (NOK 1498.4) between the two groups. 
However, due to sample size differences between the alcoholic and non-alcoholic groups, the 
cost dispersion from the mean was higher in the alcoholic group than in the non-alcoholic for 
all diagnoses except the Erysipelas (A46). The difference of the variability of hospital 
treatment cost for the two groups was worse for the unspecified Asthma (J459) diagnosis. In 
this diagnosis, the dispersion of the cost for the alcoholic group (SD = 103,724.6) was six 




Table 4-3: The average cost (in NOK) and Length of stay (in days) by gender between alcohol and non-alcohol 
consumer 
  (1) (2) (3) (4) (5) (6) 
Diag  Men Women Both 
 non-alcohol alcohol non-alcohol alcohol non-alcohol alcohol 
 
A46 
Cost 33400.7 41787.9 34407.0 42314.6 33769.41 41986.18 
(26490.3) (18442.8) (18018.3) (27379.1) (23740.64) (22181.43) 
LOS 4.891 6.277 5.241 6.750 5.019397 6.454902 
(4.941) (4.755) (5.669) (6.125) (5.220706) (5.305335) 
        
 
E86 
Cost 24525.4 35302.3 22716.7 27783.2 23460.14 31103.83 
(26541.2) (31394.3) (15904.4) (20490.7) (20928.73) (26076.24) 
LOS 3.232 4.885 3.911 4.427 3.631579 4.629442 
(5.215) (5.086) (4.899) (4.693) (5.036261) (4.863415) 
        
 
J459 
Cost 30683.1 39139.1 30137.5 58736.4 30315.03 52060.41 
(18585.5) (20054.9) (14535.8) (126783.9) (15953.47) (103724.6) 
LOS 2.387 2.968 2.253 4.600 2.296651 4.043956 
(3.685) (2.927) (2.452) (6.209) (2.908845) (5.360166) 
        
 
N10 
Cost 31123.8 33895.4 27934.3 32661.4 28847.54 33225.69 
(11705.2) (12616.0) (10435.2) (11027.8) (10906.18) (11770.9) 
LOS 5.080 5.972 4.023 6.094 4.325739 6.038462 
(4.384) (4.163) (3.766) (4.457) (3.980288) (4.316181) 
        
 
R074 
Cost 8416.8 9962.0 8379.8 9813.9 8399.712 9898.11 
(4153.0) (7355.2) (3880.8) (7180.3) (4029.49) (7278.534) 
LOS 1.028 1.412 1.019 1.439 1.023851 1.423466 
(1.144) (1.640) (1.199) (1.887) (1.169523) (1.750518) 
        
 
R101 
Cost 12861.7 20107.9 13548.1 16837.8 13275.15 18418.96 
(5022.1) (18552.9) (9261.8) (15718.9) (7858.973) (17178.18) 
LOS 1.355 2.989 1.524 2.394 1.457115 2.681319 
(1.864) (5.574) (2.066) (3.217) (1.988899) (4.509975) 
        
 
R509 
Cost 29328.7 37158.0 31070.5 35199.9 30158.34 36119.02 
(12687.2) (18298.3) (17421.7) (17882.1) (15132.82) (18011.77) 
LOS 3.658 3.348 4.348 4.269 3.986842 3.836735 
(4.003) (3.622) (5.288) (4.939) (4.665863) (4.373524) 
        
 
R568 
Cost 17908.4 21637.6 17244.1 20340.2 17630.71 21153.02 
(8290.9) (12275.8) (9224.3) (13902.4) (8694.133) (12881) 
LOS 1.935 2.894 2.293 2.855 2.084323 2.879518 
(2.266) (4.081) (2.557) (4.721) (2.397237) (4.3174) 
        
Standard deviation in parentheses 
 
The total cost variations between the alcoholic and non-alcoholic groups explained above 
were also found to be true for both female and male patients (table4.3 and table 4.4). The 




unspecified asthma (J459) diagnosis was very high for the alcoholic group when compared to 
the non-alcoholic group. The female alcoholic patients had an average cost of NOK 58,736.4 
(SD = 126,783.9), which very high when compared to the average treatment cost for non-
alcoholic female patients (NOK 30,137.7; SD = 14,535.8). This huge difference among the 
female groups was found to be due to outliers. Two female patients with very high cost of 
treatment (NOK 358,004 and NOK 958,940) affected both average treatment cost and its 
standard deviation. However, even after the outliers were excluded, the mean cost (38433.19) 
and standard deviation (20150.55) for the alcoholic group were found to be higher than that of 
the non-alcoholic group.  
As table 4.3 and table 4.4 show, the average treatment cost for non-alcoholic men and women 
were not that much different from one another. For instance the diagnoses like A46, R101, 
and R509, the average hospital treatment cost for female patients were slightly higher than 
that of male; whereas the rest of the diagnosis, the average hospital treatment cost for men 
was slightly higher than that of women. The highest cost variation between the two gender 
groups being N10, which men had treatment cost of NOK 3189.6 more than women. 
The average treatment cost of the alcoholic group was not also that much different between 
men and women except for the unspecified Asthma (J459). Hospital treatment cost for female 
identified as an alcoholic based on diagnostic history had NOK 19597.4 and NOK 526.7 more 
than male (also identified as alcoholic) for treatment of the unspecified Asthma (J459) and 
Erysipelas (A46). All other six diagnosis male treatment cost was higher than female 
treatment cost (table 4.3; table 4.4). While the inter-group-gender comparison of average 
treatment cost showed only slight differences within each group category, except J459; the 
intra-group-gender comparison between the two groups had showed immense difference. This 
applies to all of the 8 specific conditions and both for men and women.  
The four figures (4.2 – 4.5) below, the alcoholic group is depicted on the right side of the 
graph whereas the non-alcoholic group is depicted on the left side. Age and gender were 
depicted on x-axis. The comparison was within or between the right and left sides of the 
figures by gender/age-group, and same specific disease diagnosis. In order to understand 
better whether age factor was influencing the average hospital treatment cost variation 
between and among the groups in table 4.3 and table 4.4, a graphical representation for mean 





Table 4-4: Mean Cost and LOS difference between and among groups presented in table 4.3 
    (1) (2) (3) (4) (5) (6) (7) (8) 
 Table 4.3 
Column  
 A46 E86 J459 N10 R074 R101 R509 R568 
Both Gender          
Alcohol – Non-alcohol  
(6) – (5) 
Cost 8216.8 7643.7 21745.4 4378.2 1498.4 5143.8 5960.7 3522.3 
LOS 1.436 0.998 1.747 1.713 0.400 1.224 -0.150 0.795 
N 2575 596 718 1858 12664 1208 478 1008 
Female           
Alcohol – Non-alcohol  
(4) – (3) 
Cost 7907.6 5066.5 28598.9 4727.2 1434.0 3289.7 4129.4 3096.1 
LOS 1.509 0.517 2.347 2.071 0.420 0.869 -0.0788 0.562 
N 946 345 483 1286 5795 712 233 414 
Male           
Alcohol – Non-alcohol  
(2) – (1) 
Cost 8387.2 10776.9 8456.0 2771.6 1545.2 7246.2 7829.3 3729.2 
LOS 1.386 1.653 0.580 0.892 0.384 1.633 -0.310 0.960 
N 1629 251 235 572 6869 496 245 594 
Alcohol Group           
Female – Male   
(4) – (2) 
Cost 526.7 -7519.0 19597.4 -1234.0 -148.1 -3270.1 -1958.1 -1297.5 
LOS 0.473 -0.458 1.632 0.123 0.0277 -0.595 0.921 -0.0394 
N 255 197 91 234 1679 182 98 166 
Non-alcohol Group           
Female – Male  
(3 ) – (1) 
Cost 1006.3 -1808.6 -545.6 -3189.6 -36.92 686.4 1741.8 -664.4 
LOS 0.350 0.679 -0.134 -1.056 -0.00877 0.169 0.690 0.358 
N 2320 399 627 1624 10985 1026 380 842 
           
           
A46 – Erysipelas; E86 – Volume depletion; J459 – Asthma, unspecified; N10 – Acute tubulo-interstitial nephritis; R074 – Chest pain, unspecified; R101 – Pain  localized to 





Figure 4-2: Women Average treatment cost (in terms of 1000 NOK) by age group in 2008 
 
A46 – Erysipelas; E86 – Volume depletion; J459 – Asthma, unspecified; N10 – Acute tubulo-interstitial nephritis; R074 – 
Chest pain, unspecified;R101 – Pain  localized to upper abdomen; R509 – Fever, unspecified; R568 – Other  and unspecified 
convulsions 
As mentioned before age was categorized into seven groups in the descriptive statistics. The 
age factor was depicted on the x-axis while the mean cost was depicted on the y-axis. With 
exception of the unspecified chest pain (R074), all age-groups of women had close and slight 
different average treatment cost for both within age-groups and between the age-groups. The 
within-age-group variation was high for the unspecified asthma (J459), and volume depletion 
(E86) diagnoses of the alcoholic group. As the figure 4.2 shows, alcoholic female of age-
group 60 – 69 had relatively the highest average treatment cost for the unspecified asthma. 
This indicates that the results shown on table4.3 and table 4.4 for unspecified asthma was 
heavy affected by the age factor, and the outlier effect mentioned before happens between 60 
– 69 age group of the female patients. The age-group 40 – 49 had also higher average 
treatment cost for unspecified asthma (J459) than other age-groups. In case of volume 
depletion diagnosis, average treatment cost was relatively low for younger age-groups of 18 – 
19 and 20 – 29 than for other older age-group categories. For this diagnosis, the youngest age-
group (18 – 19) had the lowest average treatment cost. 
A similar pattern was found in men’s hospital treatment cost, except for the unspecified 
asthma. This is shown in figure 4.3 below. The view of the two figures, figure 4.2 and figure 
4.3, which look like different should not be confused. It is only the scaling of the two figures 
that differ. This was caused by the outlier effect of unspecified asthma treatment cost for 

































































female treatment cost. Age-groups 40 – 49 and 60 – 69 had higher average treatment cost for 
some of the diagnoses (A46, E86, and J459). 
Figure 4-3: Men average treatment cost (in terms of 1000 NOK) by age group in 2008 
 
A46 – Erysipelas; E86 – Volume depletion; J459 – Asthma, unspecified; N10 – Acute tubulo-interstitial nephritis; R074 – 
Chest pain, unspecified;R101 – Pain  localized to upper abdomen; R509 – Fever, unspecified; R568 – Other  and unspecified 
convulsions 
The cross comparison of the average treatment cost between the alcoholic and non-alcoholic 
group in both women and men, indicate that the alcoholic group had higher average treatment 
cost than the non-alcoholic group for all of these diagnoses. Simple mean comparison for the 
treatment cost differences and variations explained above is not enough to conclude whether 
the alcoholic group’s higher treatment cost matters (strength of the differences); it is 
important to control outliers and assess the significance of these variations.   
4.6.2 Descriptive Statistics for LOS 
So far it was described only the variations from the cost perspectives. And as mentioned 
above the main variables of interest was not only the cost but also the length of stay (LOS). In 
addition to table 4.3 and table 4.4, the average LOS by gender and age-group are also 
presented in figure 4.4 and figure 4.5 for women and men respectively. As table 4.3 and table 
4.4 indicate, the mean variation of LOS between the two groups was small for all diagnoses 
with the highest variation being unspecified asthma (J459) and Acute tubulo-interstitial 
nephritis (N10) diagnoses. In these two diagnoses, the alcoholic group had 1.747 and 1.713 
longer LOS than the non-alcoholic group respectively (Table 4.4). Table 4.4 also indicates 
that women had longer LOS for most of the diagnoses than men for both alcoholic and non-

































































Figure 4-4:  Women’s average length of stay for 8 selected specific diagnoses by age-group in 2008 
 
A46 – Erysipelas; E86 – Volume depletion; J459 – Asthma, unspecified; N10 – Acute tubulo-interstitial nephritis; R074 – 
Chest pain, unspecified;R101 – Pain  localized to upper abdomen; R509 – Fever, unspecified; R568 – Other  and unspecified 
convulsions 
The average LOS variations between men and women within same group and diagnosis were 
small. However, variations between alcohol and non-alcohol groups among the women 
groups were bigger than variations among men groups for diagnoses like erysipelas (A46), 
unspecified asthma (J459) and acute tubulo-interstitial nephritis (N10). Moreover the outlier 
effect for unspecified asthma (J459) treatment cost of the alcoholic females as mentioned 
several times before, was not detected in case of LOS.  
Figure 4-5: Men’s average length of stay for 8 selected specific diagnoses by age-group in 2008 
 
A46 – Erysipelas; E86 – Volume depletion; J459 – Asthma, unspecified; N10 – Acute tubulo-interstitial nephritis; R074 – 
Chest pain, unspecified;R101 – Pain  localized to upper abdomen; R509 – Fever, unspecified; R568 – Other  and unspecified 
convulsions 
The two figures (figure 4.4 and figure 4.5) show great average variations of LOS (in days) 
among and between different age-groups. While it is difficult to conclude from the figures 
that the older the patient is the longer the LOS, yet the age-groups above 40 years old seem to 




























































































































groups. The variations were wider and more complex for the alcoholic group than for the non-
alcoholic group. 
The above descriptive statistics indicate the need for developing an appropriate statistical 
method in order to approximate the necessary parameters, and deal with group specific 
characteristics like gender and age-groups. The following section explains the models and 
statistical parameters applied in the study. 
4.7 Model 
The preceding descriptive statistics can not be used to conclude cost and LOS variations 
between the two groups. These kinds of descriptive statistics do not measure the errors and 
significance level. Neither do they give a clear picture of what kind of model appropriate for 
analyzing. In the previous sections it was mentioned that the data was observational data in 
which the two groups (i.e. the alcohol group – those with alcohol related diseases and non-
alcohol group – those without alcohol related diseases) were to be compared.  
As mentioned in the previous sections the main explanatory variable “the alcohol factor” is 
categorical. Age and gender variations were also considered. Gender factor was applied 
separately for female and male observations; in other words the model was applied separately 
for male and female observations. The advantage of the separate regression is that it is easier 
to capture the cost and LOS variations of the two groups (Alcohol vs Non-alcohol) among the 
same gender. A combined model, where the variations between male and female were tested, 
is presented in the appendix-A.I. The age-groups were not evenly distributed; in some cases 
empty cells or very small cells for some age-groups were encountered; this can be observed 
from figures 4.2, 4.3, 4.4, and 4.5. Because of this problem age was categorized into two 
groups i.e. young (18 – 49) and old (50 – 79). This means the two explanatory variables 
(alcohol and age factor), which were both dummy variables, were applied in the model of the 
main result analysis. The non-alcoholic (those without alcohol co-morbidity) and the young 
age-group (18 – 49) were taken as the reference category. The regression results with seven 
age-groups are presented in appendix A.IV, the possibility of empty cells has to be taken into 
consideration when interpreting the results in appendix A.IV. 
The two variables of interest cost and LOS shared these explanatory variables, however, the 
two variables had different nature; therefore, two different models were applied for cost and 




4.7.1 Length of Hospital Stay (LOS) 
 
The length of stay (LOS), measured in days, is a variable of interest in the literature of 
epidemiology (Lechman and Duder, 2009) particularly in health economics. The cost of a 
particular disease, among other things, depends on LOS. Estimation of average LOS says 
something about the expected cost behavior. In theory longer LOS means higher cost and 
shorter LOS means lower cost (Northcott and Llewellyn, 2003). Each additional day a patient 
spends in hospital beds costs more. Therefore LOS becomes an important health indicator 
(Ravangard et al., 2011). When searched in PubMed the term “length of hospital stay” 
resulted in more than 60,000 findings.  How long do patients identified as alcoholic (based on 
alcohol co-morbidities) spend in hospital treatment for other diagnosis (unknown the 
association of alcohol)? This was the focal point of this study; and the LOS of 8 specific 
diagnoses not usually considered for alcohol cost estimation was selected and included in the 
analysis. Two groups alcoholic and non-alcoholic patients, who were treated with same 
diagnosis, were compared. 
4.7.1.1 Model Framework for LOS 
The nature and distribution of the dependent variable usually determines what kind of model 
to be applied. As table 4.3 displays, LOS was a discrete count variable (i.e. LOS = 0, 1, 2 
….i). Whether patients remained in hospital bed for the same diagnosis or for a different 
condition were not discoverable. It was assumed that patients stayed in hospital for the 
treatment of same diagnosis. Patients stayed less than 24 hours were also included as zero.  
The distribution of the data was tested using different methods, like histogram; kernel density 
estimate; pnorm; and Shapiro-Wilk W test (p<0.001). The normality assumption was unable 
to accept.  





The nature of the dependent variable limits the normality of the residuals; the observational 
data with nonnegative integer outcome (the count data) is usually skewed heavily to right  and 
nonlinear because of its discrete positive integer values (Cameron and Trivedi, 1999; Lord 
and Park, 2010). One of the common features and structures in health economics and many 
other applied fields is the count nature data; like number of days patients stayed in hospital or 
number of patients treated or dead. Models for count data are widely applied for such kind of 
data (Greene, 2008). 
After careful exploration of the alternative distributions of the LOS variable, a Poisson data 
distribution was the closest distribution. All the 8 diagnoses included in this study follow 
similar pattern as the aggregate histogram below. The graphical distribution of LOS for each 
diagnosis is presented in appendix (A.V). 
Figure 4-7: The length of stay distribution 
 
According to Greene (2008) the Poisson models are the foundation for almost all count 
models’ framework, but its restrictive assumption of equality between variance and mean 
confines the applicability of this type of model other count models are mostly favored, like 
the negative binomial model. The integration of the observed and unobserved variance 
variations and the conditional means (Park, 2005) is the main motive why the later model was 
preferred. Moreover, although the structure of the above graph and the nature of the data 
(count data) fit with Poisson distribution; the assumption of the Poisson distribution of equal 
mean and variance was violated as indicated in the table 4.3 above. The presence of 
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hypothesis of α = 0 were rejected in all models. A negative binomial model was chosen as an 
appropriate method of analyzing and dealing with the overdispersion. 
4.7.1.2 Model Specification for LOS 
The negative binomial model formulas for count data are derived from the Poisson model 
function (Cameron and Trivedi, 1999): 
          
         
  
                                                
                           
And a density function g(ν|α) 
Where y is the count variable of poison distribution (the length of stay measured as 0 1 2 3 
4…) conditional random parameters λ; µ is the deterministic function of the explanatory 
variables Xi (like age and alcohol consumption in this case); and ν is random part of the 
unobserved heterogeneity of λ.  
By integrate out ν Cameron andTrivedi (1999) derived the following negative binomial 
regression: 
          
        
       
 
   
     
 
   
 
 
     
 
 
                       
                                       
Where α is the overdispersion; (.) is the gamma function of the probability distribution. The 
negative binomial distribution fit with Poisson distribution if α=0. The ordinary binomial 
regression considers zero outcomes; but this could be a problem if there are excess zeros. The 
variable LOS had zero value, and was not excluded from the data; a zero value for LOS 
means patients were treated for these specific diseases but not hospitalized. A Vuong test was 
applied to test if the ordinary negative binomial model was appropriate. The test compares a 
zero-inflated negative binomial with the ordinary negative binomial. The Vuong test results 
were negative and small t-value (|t|<|1.96|), which means an asymptotically distributed 
standard normal. In other words the Vuong test indicated indifference between the two 
models, either of these two models could be applied (Vuong, 1989).  
Negative binomial regression was used to analyses the variations of LOS between the two 
groups. Heteroscedasticity was also detected and due to sample size differences heterogeneity 




control for heteroscedasticity. Interaction terms was also tested between alcohol related co-
morbidities and age-category; no significant interaction factor was discovered and therefore, 
the interaction factor is removed from the analysis. 
The model was applied separately for female (table 5.3) and male (table 5.5) observations 
However, LOS variation between female and male was tested by adding the gender factor to 
the model; the result is presented in appendix A.I -Table 8-1. 
4.7.2 Hospital Treatment Cost 
Cost is one of the two main variables of interest in this paper. The hospital cost is calculated 
based on Diagnosis Related Groups (DRGs). Norway partly finances somatic hospital 
treatment cost by DRGs system since 1997 (CHRISTENSEN et al., 2004) to control cost and 
improve hospital productivity and efficiency (Mishra et al., 2001). DRG is a fixed per-case 
payment system usually made in prospective payment on hospital admission (OTA, 1983). Its 
formulation is based on LOS and inputs required for treatments to group of homogeneous 
patients (Fetter et al., 1980; Street et al., 2012). This system standardizes the hospital 
treatment cost for patients with identical diagnosis and character. The estimation of cost using 
DRGs might overestimate or underestimate the actual cost incurred (Mishra et al., 2001). In 
this study, it was intended to check whether hospital cost was consistent to the findings of 
LOS; and to emphasize variations between alcoholic (those with alcohol co-morbidities) and 
non-alcoholic (those without such co-morbidities).  
4.7.2.1 Model Framework for Cost 
Health care costs are commonly known with the heavily skewedness to right; when this is the 
case, the ordinary least square (OLS) parameters are not best estimators (Diehr et al., 1999; 
Buntin and Zaslavsky, 2004). The nonnegative nature of the outcome variable and the 
presence of few heavy users are confining the applicability of the symmetrical distribution 
models (Cantoni and Ronchetti, 2006). There are other models which health economists 
prefer to apply when assumptions like normality is violated; among them are the log 
transformation method and the generalized linear regression model (GLM). Log 
transformation is a method of producing the log of the dependent variable before OLS is 
applied; while log transformation reduces the skewness, deals with outliers, and approximates 
to a normal distribution of the health care costs (Diehr et al., 1999; Buntin and Zaslavsky, 
2004), the log coefficients are not a convenient way of transmitting the results of the health 
care costs (Buntin and Zaslavsky, 2004). Therefore, retransformation of the log coefficient by 




required (Buntin and Zaslavsky, 2004). This process is complex and data is usually lost on the 
way (Buntin and Zaslavsky, 2004). For this reason an alternative method called generalized 
linear regression model first developed by Nelder and Wedderburn in 1972 (Fox, 2008) is 
commonly preferred and widely applied in health care cost analysis. The GLM coefficients 
presented in exponential way helps to avoid the retransformation of coefficients to the original 
non-log scale; instead it is directly interpretable by using a multiplicative method (Buntin and 
Zaslavsky, 2004). 
When regression diagnoses was applied to cost data of all the 8 diagnoses; as usual the 
presence of heavily right-skewed distribution was found (Appendix-A.V). Besides that, other 
assumptions of ordinary linear regression were not violated. The normality distribution was 
not able to get even after log transformation of the cost. The generalized linear regression 
model was chosen, to give a picture of cost comparison between those with alcohol co-
morbidities and those without alcohol co-morbidities. Moreover, variations of the significance 
level were found between models with robustness and those without robustness. This implies 
the presence of heteroscedasticity. Modified Park Test was applied to determine the GLM 
family distribution (Manning and Mullahy, 2001); and as suggested by Cantoni andRonchetti 
(2006), a combined model of GLM (gamma family) and robust approach was used to deal 
with these issues.  
4.7.2.2 Generalized Linear Regression Model Specification for Cost 
According to Fox (2008) generalized linear model specification is based on three main parts: 
i. The conditional distribution of the outcome variable Yi is determined by a random 
component belonging to the exponential families, in this case cost had gamma family 
distribution. 
ii. A linear predictor (In this paper Xi are dummy variables and linear prediction is not 
important)  
                                   
iii. And a conditional mean link function g(.) for the transformation of the outcome 
variable, μi = E(Yi) into a linear predictor 
                                             
             
With log link  
                 
                




Where y is dependent variable (cost) and xi represents the explanatory variables like alcohol 
(based on alcohol related co-morbidity), gender, and age-category. 
And relationship between mean and variance  
               
  
Where ϕ is the dispersion parameter; v determines what kind of GLM family is suitable. If v = 
0 a Gaussian, v = 1 a Poisson, v = 2 a Gamma, and if v = 3 an Inverse Gaussian or Wald 
family. Modified Park Test applied indicated that v ~= 2; and there GLM with gamma family 
was applied. A gamma distribution which has two parameters scale ω > 0 and shape ψ > 0 
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 for y > 0 , where Г(.) is the gamma function, ψ is the shape parameter, 
and ω is the scale parameter.  The two parameters scale and shape deals with spread and 
skewness issues respectively. The GLM with gamma distribution has E(Y) = ωψ and V(Y) = 
ϕμ2. Where the dispersion term ϕ is equal to 1/ψ (Fox, 2008).  
This GLM was applied separately for female (table 5.4) and male (table 5.6) observations as 
for NBR model. However, cost variation between female and male was tested by adding the 
gender factor to the model; the result is presented in appendix A.I -Table 8-2. 
4.7.3 Statistical Methods 
Statistical analyses were computed using Stata data analysis and statistical software packages 
(Stata/SE 10.1; Stata/MP 11.1 and Stata/SE 12). Simplified tables were created using the user 
command option estout developed by Jann (2007). The conventionally applied p-value of less 
than 5% was used to reject the null hypothesis of zero coefficients; however, lesser p-values 
like 1% and 0.1% were also marked, to emphasize the higher level of significance. The 
coefficient output of negative binomial regression and generalized linear regression model 
were in log scale. However, the log scale is not a convenient way to interpret the results. The 
log scale was transformed into an exponential coefficient scale (rate ratio). The percentage 
change of the dependent variables expressed as (e
β
 – 1)*100% was also used to interpret the 
coefficients. Both univariate and multivariate analysis was performed, but only multivariate 






5.  Results Analysis for LOS and Cost  
The summary statistics by gender, age-group and alcohol factor displayed in table 5.1 and 
table 5.2 were applied to NBR for LOS and GLM regression for cost respectively. These two 
tables provide the mean and the standard deviation of length of hospital stay (LOS) and 
hospital treatment cost. The results of these tables were merely intended to add what had been 
discussed in previous section of descriptive statistics. What distinguishes these summary 
statistics in table 5.1 and table 5.2 from previous descriptive statistics is that age was 
classified as young (18 – 49) and old (50 – 79) as for the regression models for LOS and cost. 
The summary statistics in these two tables can be observed the individual characteristics 
which the two models were applied to compare. As the tables 5.1 and 5.2 indicate the majority 
of the diagnoses, the alcoholic group had Longer LOS and higher cost, but there are cases 
which the non-alcoholic group had longer LOS and higher cost.  
The variations of group means were tested using negative binomial regression (NBR) for LOS 
and generalized linear regression model (GLM) for cost as explained in the previous section. 
The NBR and GLM compares the group means classified in table 5.1 and table 5.2 below 
respectively. The regression was applied separately for male and female as mentioned before. 
This was done to find a simple way of testing mean variations among group within same 
gender. In this way the females of different age-groups and alcohol factor (Alcoholic vs Non-
alcoholic) were compared. Mean variation between male and females were also tested and 
presented in the appendix-A.I. 
Results of each gender groups were presented separately. Table 5.3 and table 5.4 below 
provide exponentiated coefficients of NBR for LOS and GLM for cost respectively for 
women observations. Table 5.5 and table 5.6 below provide the exponential coefficients for 
LOS and cost for men observations. Statistical significance between the two groups was 
found. Although the results of the regression for all of the 8 diagnoses were displayed 




Table 5-1: The mean and standard deviation of LOS by gender and age 
   Mean & standard deviation of LOS   
Gender Age Group A46 E86 J459 N10 R074 R101 R509 R568 
  Non-alcohol 3.979 1.833 1.843 4.678 0.960 1.346 3.198 1.700 
   (4.504) (1.788) (2.261) (4.703) (1.135) (1.845) (4.014) (1.800) 
 18 – 49 n 619 54 89 121 2,695 237 86 300 
  alcohol 4.821 6.500 1.375 4.417 1.370 2.488 3 3.204 
   (4.877) (5.600) (1.302) (2.353) (1.524) (4.659) (1.936) (5.370) 
Male  n 28 12 8 12 230 41 9 49 
           
  Non-alcohol 5.555 3.918 2.809 5.221 1.084 1.368 4.009 2.305 
   (5.137) (6.138) (4.452) (4.264) (1.147) (1.894) (3.976) (2.817) 
 50 – 79 n 851 110 115 344 3,219 171 113 190 
  alcohol 6.588 4.627 3.522 6.168 1.425 3.426 3.432 2.618 
   (4.689) (4.991) (3.146) (4.306) (1.677) (6.282) (3.941) (2.446) 
  n 131 75 23 95 725 47 37 55 
           
Female  Non-alcohol 3.744 2.859 1.768 3.338 0.932 1.324 4.103 2.021 
   (3.707) (4.408) (2.020) (2.989) (1.093) (1.856) (5.113) (2.456) 
 18 – 49 n 234 85 220 739 1,555 413 87 233 
  alcohol 5.176 2.071 3.957 3.676 1.590 2.174 2.688 2.559 
   (4.066) (1.730) (5.448) (2.266) (2.535) (3.951) (2.774) (2.776) 
  n 17 14 23 34 122 46 16 34 
           
  Non-alcohol 5.810 4.507 2.778 5.229 1.057 1.927 4.574 2.824 
   (6.163) (5.075) (2.758) (4.602) (1.242) (2.391) (5.462) (2.676) 
 50 – 79 n 616 150 203 420 3,516 205 94 119 
  alcohol 7.089 4.771 5 6.978 1.409 2.604 4.972 3.214 
   (6.453) (4.891) (6.679) (4.734) (1.727) (2.331) (5.532) (6.379) 
  n 79 96 37 93 602 48 36 28 





Table 5-2:  Mean & standard deviation of Cost by age-category and gender 
Gender Age Group A46 E86 J459 N10 R074 R101 R509 R568 
  Non-alcohol 31236.3 19527.7 27704.0 30318.4 8164.4 12545.9 27070.2 16639.6 
   (17639.8) (12934.3) (12291.6) (12908.1) (2726.9) (5228.1) (8020.6) (7587.1) 
 18 – 49 N 619 54 89 121 2695 237 86 300 
  Alcohol 37985.1 46853.4 30282.3 29945.8 11033.3 19063.9 29198.1 22866.2 
   (21164.9) (52892.7) (9643.4) (5467.0) (9873.2) (13453.2) (5674.7) (14748.2) 
  N 28 12 8 12 230 41 9 49 
Male           
  Non-alcohol 34975.1 26978.8 32988.7 31407.1 8628.0 13299.4 31047.5 19911.9 
   (31315.1) (30880.8) (22049.3) (11258.0) (5036.8) (4701.7) (15127.6) (8954.9) 
 50 – 79 N 851 110 115 344 3219 171 113 190 
  Alcohol 42600.7 33454.1 42219.7 34394.3 9622.1 21018.6 39094.2 20543.0 
   (17792.8) (26541.8) (21918.5) (13181.1) (6322.4) (22176.7) (19791.1) (9565.9) 
  N 131 75 23 95 725 47 37 55 
           
Female  Non-alcohol 31382.3 17472.7 28999.1 26388.1 8244.1 12666.9 28383.4 17066.1 
   (14052.7) (11200.0) (14566.7) (8906.3) (3643.3) (5106.8) (11121.0) (10249.9) 
 18 – 49 N 234 85 220 739 1555 413 87 233 
  Alcohol 40455.6 14900.8 52518.6 28788.0 10350.6 17247.7 38084.2 17496.4 
   (18899.1) (8991.2) (70667.1) (7390.4) (8754.0) (21511.8) (29603.8) (6808.5) 
   17 14 23 34 122 46 16 34 
           
  Non-alcohol 35556.0 25688.4 31371.3 30654.8 8439.9 15323.3 33557.5 17592.6 
   (19198.1) (17376.8) (14436.7) (12231.2) (3980.3) (14213.9) (21449.4) (6808.4) 
 50 – 79 N 616 150 203 420 3516 205 94 119 
  Alcohol 42714.7 29661.9 62601.6 34077.5 9705.1 16445.0 33918.0 23793.2 
   (28962.2) (21039.5) (152485.7) (11806.5) (6820.9) (6747.1) (9212.1) (18906.5) 
  N 79 96 37 93 602 48 36 28 




5.1 Erysipelas (A46) 
As shown in table 4.1, 2,575 patients, who were registered in Norwegian Patient Registry 
(NPR) of 2008 for erysipelas treatment, were included in this study. While almost half of 
these patients spent one day at hospital, yet there were patients who spent as much as 60 days 
for treating the same diagnosis. 2,320 of these patients were non-alcoholic patients and the 
rest (255) were alcoholic patients (based on diagnostic history). Though the number of 
alcoholic group admitted for erysipelas was much less than non-alcohol group, the average 
LOS was longer and the mean cost was higher for the alcoholic group than for the non-
alcoholic group. The longer LOS and higher cost were also true for women and men as well 
as both age-groups as shown in table 5.1 and table 5.2 respectively.  
Average length of treatment (in days) comparison in table 5.1 also shows that the older the 
individual the longer was the LOS for alcoholic group. This applies for both women and men. 
For instance as table 5.1 shows Age-group(18 – 49) had an average  LOS(days) 5.2 (sd = 4.1) 
for women, and 4.8 (sd = 4.9) for men; whereas Age-group(50 – 79) had higher average LOS 
(days) 7.1 (sd = 6.5 ) and 6.6 (sd = 4.7)  with the corresponding gender. The cost pattern was 
also similar as shown in table 5.2. However, the big standard deviation makes such kind of 
comparison less reliable. 
 The negative binomial regression and generalized linear regression model explained in the 
model section above were presented in table 5.3 and table 5.4 for women, and table 5.5 and 
table 5.6 for men. The first column of the table 5.3, table 5.4, table 5.5 and table 5.6 were 
presented exponentiated coefficients of the NBR and GLM results of LOS and cost for 
erysipelas treatment. As table 5.3 and table 5.5 (for LOS) and table 5.4 and table 5.6 (for cost) 
indicate the exponential coefficients of the two explanatory factors (alcohol-group-category, 
and Age-category) for both genders indicate a positive increase of the LOS as well as cost 
when compared to the references groups (non-alcohol and Age-group(18 – 49). 
In case of LOS, the Wald (χ2) illustrates that the model for LOS versus the two explanatory 
variables was statistically significant with χ2 = 41.79 (p<0.001) for women, and χ2= 52.86 
(p<0.001) for men (Table5.3; Table 5.5). Since pseudo-R
2
 is not a true measure of the 
explained variance, it was excluded from the results. Instead the predicted and observed LOS 
of the model was presented in appendix-A.V. Moreover, other things being constant, it was 
found a slightly longer LOS for the alcoholic group than for the non-alcoholic group. This 




longer LOS), and men (β= 1.191(se = 0.0783; p<0.01) times longer LOS). This means that 
when other factors are kept constant, women of the alcohol group had 24.7% longer LOS days 
than non-alcoholic women group. The percentage variation is calculated as (e
β
 – 1)*100.  
Table 5-3: The effect of alcohol (alcohol-related diseases) to women’s length of hospital stay for 8 diagnoses  
Model (1) (2) (3) (4) (5) (6) (7) (8) 
LOS A46 E86 J459 N10 R074 R101 R509 R568 













 0.935 1.206 
 (0.121) (0.127) (0.355) (0.0862) (0.0734) (0.241) (0.168) (0.244) 
Age
♥
         
50 – 79  1.536*** 1.675** 1.522*** 1.592*** 1.102** 1.408** 1.220 1.372** 
 (0.112) (0.278) (0.157) (0.0805) (0.0406) (0.148) (0.194) (0.165) 
















 (0.234) (0.422) (0.137) (0.107) (0.0287) (0.0898) (0.494) (0.160) 
         
Wald(χ2) 41.79*** 9.80*** 33.05*** 122.97*** 58.99*** 26.16*** 1.62 6.98 


















N 946 345 483 1286 5795 712 233 414 
Exponentiated coefficients; robust standard errors in parentheses (se); ♣ Likelihood-ratio test of alpha=0 
*
 p < 0.05, 
**
 p < 0.01, 
***
 p < 0.001 
♥ Reference groups are those without alcohol-related co-morbidity; age-group 18 – 49 
A46 – Erysipelas; E86 – Volume depletion; J459 – Asthma, unspecified; N10 – Acute tubulo-interstitial nephritis; R074 – 
Chest pain, unspecified;R101 – Pain  localized to upper abdomen; R509 – Fever, unspecified; R568 – Other  and unspecified 
convulsions 
The age factor had also a positive effect with longer LOS for the old age-group of both 
genders. The old women had more than 50% longer LOS than the young women. This huge 
difference between age groups of women was found to be statistically significant (1.536 times 
longer: se = 0.11; p<0.001). Differences of LOS between the age-groups among the men was 
also high as 40% longer LOS for the old men than for young of the same gender. Again the 
variation among the age-men-groups was significant. The exponentiated coefficients of LOS 
shown in table 5.5 indicates that old men had 1.394 (se = 0.0745; p<0.001) times longer LOS 
than the reference age – group. 
The GLM regression results (table 5.4 and table 5.6) were consistent with the negative 
binomial regression for both genders as well as the two age-categories. The mean treatment 
cost of erysipelas diagnosis (A46) for young female (18 – 49), which had no alcohol-related 
co-morbidities, was NOK 31507.4 (se = 902.2). However, other things being equal, the mean 
treatment cost of erysipelas diagnosis for young alcoholic female patient (those with alcohol 




patients without alcohol co-morbidities (table 5.4). As shown in table 5.6, the effect of alcohol 
factor on the treatment cost of erysipelas diagnosis (A46) for male patient was similar to that 
of the female. Small, but significant positive effect of the age factor was found both among 
men and women. When other things are kept constant, the old age-group (50 – 79) had 12.7% 
(p<0.001) for female and 12% (p<0.01) for male higher average treatment cost than the young 
age-group of the respective gender (Table 5.4 and Table 5.6) 
Table 5-4: The effect of alcohol (alcohol-related diseases) for female treatment cost of 8 selected diagnoses 
Model (1) (2) (3) (4) (5) (6) (7) (8) 
Cost A46 E86 J459 N10 R074 R101 R509 R568 









 1.219 1.120 1.163 
 (0.0820) (0.0904) (0.513) (0.0350) (0.0330) (0.134) (0.101) (0.0980) 
Age         
50 – 79  1.127*** 1.547*** 1.094 1.164*** 1.016 1.169* 1.116 1.079 
 (0.0397) (0.124) (0.0761) (0.0252) (0.0147) (0.0750) (0.0829) (0.0560) 
         
_cons 31507.4 16915.6 28841.6 26372.8 8288.5 12815.0 29258.2 16808.2 
 (902.2) (1104.6) (1202.1) (320.9) (96.97) (273.2) (1286.1) (643.6) 
         
Log LH♣ -10846.5 -3821.9 -5503.99 -14468.0 -58258.8 -7504.4 -2649.3 -4462.63 
N 946 345 483 1286 5795 712 233 414 
Exponentiated coefficients; robust standard errors in parentheses (se) 
*
 p < 0.05, 
**
 p < 0.01, 
***
 p < 0.001 
♣ LH = Log likelihood  
♥ Reference groups are those without alcohol-related co-morbidities; age-group 18 – 49 
A46 – Erysipelas; E86 – Volume depletion; J459 – Asthma, unspecified; N10 – Acute tubulo-
interstitial nephritis; R074 – Chest pain, unspecified;R101 – Pain  localized to upper abdomen; R509 
– Fever, unspecified; R568 – Other  and unspecified convulsions 
 
5.2 Volume Depletion (E86) 
596 patients, who were admitted for treating volume depletion, were recorded in NPR in 2008 
(table 4.1).  Most of these patients were hospitalized for at least one day. 399 patients were 
identified as non-alcoholic of which 235 were women, and 164 were men; whereas 197 
patients were identified as alcoholic patients (patients with alcohol-related co-morbidities), 
110 women; and 87 men (table 4.1).   
As table 4.3 and table 4.4 indicate, the alcoholic group had longer length of hospital stay 
(LOS), and higher treatment cost than for the non-alcoholic. The alcoholic group had an 
average LOS of 4.885 days (sd = 5.086) for men, and 4.427(sd = 4.693) days for women. 
However, the non-alcoholic group had a lower average LOS of 3.232 days (sd = 5.215), and 




for both age-groups of men, but this was not true for women age-groups. The young women 
age-group (18 – 49), who were alcoholic, had shorter LOS (2.071; sd = 1.73) than non-
alcoholic women (2.859, sd =4.408) of the same age-group. The average hospital treatment 
cost also follows the similar pattern (table 4.3, table 4.4 and table 5.2). 
 To assess the strength and significance of these variations, a negative binomial regression 
(NBR) with robust option was applied for LOS. The result of NBR is displayed in the second 
column of table 5.3 for women, and table 5.5 for men. As in the case of the erysipelas, the 
predictors (alcohol and age factor) significantly explain the variation of LOS for the volume 
depletion treatment between the alcohol and non-alcohol group. Other things being constant, 
the alcoholic men had 48% longer LOS than non-alcoholic men, this longer LOS for the 
alcoholic men was found significant at 5% level (1.48 times longer: se = 0.227; p<0.05). 
However this was not the case for women observations. No statistically significant difference 
was found between alcoholic and non-alcoholic women. While age factor had higher positive 
effect over the reference age-group, LOS variation between the age-groups was longer among 
the women than among the men. Ceteris paribus, the old women had 67.5% (p < 0.01) longer 
LOS than the young women; whereas the old men had 52.3% (p<0.05) longer LOS than the 
young men.  
GLM regression results on hospital treatment cost for the volume depletion were consistent 
with NBR when it comes to the effect of the alcohol factor (table 5.4 and table 5.6). The non-
alcoholic male patients had an average treatment cost of NOK 21970.2 (se = 2280). But male 
patients who were identified as an alcoholic patients (based on diagnostic history) had 1.421 
(se = 0.192; p<0.01) times higher cost than non-alcoholic male patients. However, as the NBR 
for LOS, the cost variations between alcoholic and non-alcoholic female patients were small 
and not significant at 5% level. The effect of age factor was also different between male and 
female models. For instance, the mean cost of volume depletion treatment for young non-
alcoholic female (18 – 49) was NOK 16915.6 (se = 1104.6). However, ceteris paribus, the old 
female patients (50 – 79) had 1.547 (s = 0.124; p<0.001) times higher treatment cost than 
young female had (table 5.4). Age factor had no significant effect among males (table 5.6). 
5.3 Unspecified Asthma (J459) 
718 patients, who were treated for unspecified asthma diagnosis, were registered in NPR of 
2008. 91 of them were identified as alcoholic, and 627 were non-alcoholic. 60 Out of the 91 




were women, and 204 were men (table 4.1). Table 4.3, table 5.1 and table 5.2 also present the 
average (mean) LOS and treatment cost of unspecified asthma for both women and men. 
Although the average length of hospital stay for alcoholic group was longer than the 
corresponding non-alcoholic for both genders, no statistically significant difference was found 
between the two groups among the men observations. However, other things being constant, 
the women, who were identified as alcoholic stayed 96% longer LOS for treatment of the 
unspecified asthma than other non-alcoholic women. This is 1.96 (se = 0.355; p<0.001) times 
longer LOS. The age factor was found to have a strong statistically significant effect for both 
genders. The old age-group had 52.2% (i.e. 1.522 times longer; se = 0.157; p<0.001), and 
60.1% (i.e. 1.601 times longer; se = 0.290; p<0.01) longer LOS for women (table 5.2) and 
men (table 5.4) respectively. 
The cost regression results displayed in table 5.4 for women and table 5.6 for men indicates 
statistically significance effect of the alcohol factor for both male and female models. 
Contrary to the NBR result of LOS for male observations, which was not found any 
significance effect of the alcohol factor, the GLM regression result of cost for male was found 
statistically significant. The average treatment cost of unspecified asthma for the alcoholic 
male was 1.228 (se = 0.119; p <0.05) times higher than the non-alcoholic male. In case of 
female model, the GML regression result was consistent to the NBR result. Both models as 
shown in table 5.3 and table 5.4 indicate strong effect of the alcohol factor for LOS and cost. 
The average cost for the non-alcoholic female was NOK 28841.6 (se = 1202.1), whereas the 
alcoholic female had 1.921 (se = 0.513; p<0.05) times this amount. In the previous section of 
descriptive statistics, it was mentioned that an outlier effect was involved for the treatment 
cost of unspecified asthma for alcoholic female observations. While the GLM deals with 
outliers in general, relatively extreme outliers could affect the result. However, even after the 
outlier observations were excluded, there was higher treatment cost for the alcoholic than for 
than non-alcoholic females; but only 1.253 (se = 0.0940; p<=0.01) times higher (result not 
shown). Age factor had higher treatment cost for old, and was significant only for male model 
(table 5.4; table 5.6).  
5.4 Acute Tubulo-interstitial Nephritis (N10) 
In 2008, 1858 patients, who were treated from acute tubulo-interstitial nephritis (ATIN) 
diseases, were included in the NPR.  234 of these patients were also diagnosed with alcohol-




diagnosed such diseases related to alcohol. Out of the 234 alcoholic patients, 127 were female 
and 107 were male (table 4.1).  
As the table 4.3 and table 4.4 indicate, longer average LOS and higher treatment cost for the 
alcoholic group was found for both genders. The longer LOS for the alcoholic was not 
common for both young and old among men. The young non-alcoholic male had little longer 
average LOS and higher cost than the young alcoholic men (table 5.1; table 5.2). The LOS 
variations between alcoholic and non-alcoholic, young and old among men were insignificant 
(table 5.5). But it is important to mention that the two explanatory factors were not found 
significant for explaining the variation of LOS of the male model (χ2(2) = 5.75, p>0.05). This 
means the model was not well explained by these two factors. 
Contrary to the male model, the LOS variation among the women was found statistically 
significant. A Wald chi-square of 122.97 with 2 degree of freedom signifies this at 5% level 
(table 5.3). Moreover, the longer average LOS in the descriptive tables was strengthened by 
the NBR result shown in table 5.3. The length of hospital stay for ATIN treatment of the 
alcoholic women was 1.272 (se = 0.0862; p<0.001) times longer than that of the non-
alcoholic women. This means, other things being constant, there were 27.2% longer LOS for 
the alcoholic than non-alcoholic among the women. LOS variations between the old and 
young women were also found to be significant. Other things being equal, the old women had 
1.592 (se = 0.0805, p<0.001) times longer LOS than the young women. 
Although the LOS variation between alcoholic and non-alcoholic among male was not found 
statistically significant, the GLM regression results indicate that alcoholic (those patients with 
alcohol-related co-morbidity) had higher statistically significant treatment cost of ATIN than 
non-alcoholic for both male (table 5.6) and female (table 5.4) models. However, only 10.5% 
higher in case of female model (table5.4) and 8.1% higher for case of male model (table 5.6). 
The age factor was statistically significant for female model only, which the older female had 
16.4% higher treatment cost than younger female. 
5.5 Unspecified Chest Pain (R074) 
Another diagnosis of interest which is not usually included when quantifying alcohol-
attributable fraction of economic loss is the unspecified chest pain. As the name suggests it is 
a type of chest pain not known the causes behind. This diagnosis had the largest sample size 
among the diagnoses selected to compare the treatment cost and length of stay between the 




There were 12,664 patients, who were treated from unspecified chest pain, were included in 
the registry of NPR in 2008 (table 4.1). More than 86% of these patients were identified as 
non-alcoholic group, whereas only 13% of them were identified as alcoholic group. While as 
other diagnoses, the alcoholic group had smaller sample size than the non-alcoholic group, it 
has the largest sample size (1,679) for all diagnoses among the alcoholic group.  955 out of 
the 1679 alcoholic group were men while the rest, about 724, were women.  
The average LOS for all patients was shorter than 2 days and slightly longer for the alcoholic 
group (table 4.2, table 5.1). The two explanatory variables significantly explain the over all 
model for both men (χ2(2) = 75.75, p<0.001) and women (χ2(2) = 58.99, p<0.001). Though 
the variations between the two groups (the alcoholic and non-alcoholic) was small, shorter 
than a half day, it was statistical significant for both genders.  
Table 5-5: The effect of alcohol (alcohol-related diseases) to men’s length of hospital stay for 8 diagnoses 
Model (1) (2) (3) (4) (5) (6) (7) (8) 














 (0.0796) (0.249) (0.227) (0.0890) (0.0544) (0.451) (0.149) (0.231) 
Age
♥
         
50 – 79  1.394*** 1.526* 1.601** 1.142 1.117*** 1.089 1.239 1.221 
 (0.0745) (0.265) (0.290) (0.106) (0.0313) (0.150) (0.183) (0.128) 
















 (0.177) (0.307) (0.225) (0.395) (0.0212) (0.118) (0.407) (0.107) 
         
Wald(χ2) 52.86*** 20.68*** 8.89* 5.75 75.75*** 14.52*** 2.73 17.85 
df 2 2 2 2 2 2 2 2 
LR(α=0)♣ 2059*** 494*** 239*** 494*** 172*** 366*** 310*** 295*** 
N 1629 251 235 572 6869 496 245 594 
Exponentiated coefficients; robust Standard errors in parentheses (se); ♣ Likelihood-ratio test of alpha=0 
*
 p < 0.05, 
**
 p < 0.01, 
***
 p < 0.001 
♥ Reference groups are those without alcohol-related co-morbidities; age-group 18 – 49 
A46 – Erysipelas; E86 – Volume depletion; J459 – Asthma, unspecified; N10 – Acute tubulo-interstitial nephritis; R074 – 
Chest pain, unspecified;R101 – Pain  localized to upper abdomen; R509 – Fever, unspecified; R568 – Other  and unspecified 
convulsions 
 
The exponentiated coefficients of the negative binomial regression (NBR) in table 5.3 and 
table 5.5 indicate that, other things being constant, treatment of the unspecified chest pain was 
1.395 (se = 0.0734; p<0.001) times longer LOS for the alcoholic women, and 1.342 (se = 
0.0544; p<0.001) times longer for the alcoholic men than for the non-alcoholic women and 
men respectively. This was 39.5% and 34.2% longer LOS for alcoholic women and men. The 
NBR results also indicate that the LOS variation among the age-groups was statistically 




The descriptive statistics in table 4.4 and table 5.2 also indicate minor variations of treatment 
cost between the alcoholic and non-alcoholic for both genders. As table 4.4 indicates, on 
average alcoholic had extra NOK 1434 for female and NOK 1545.2 for male than non-
alcoholic of the corresponding gender. The GLM regression results in table 5.4 and table 5.6 
show that these small variations between the two groups were significant. The model 
indicates that the alcoholic female had 1.169 (se = 0.0330; p<0.001) times higher cost than the 
non-alcoholic female (table 5.4). As table 5.6 indicates, the effect of alcohol factor on male 
model was similar to that of the female model. The age factor had a very small positive effect 
for both female and male models, and it was significant at 5% level only for male model. 
Table 5-6: The effect of alcohol (alcohol-related diseases) for men treatment cost of 8 selected diagnoses 
Model (1) (2) (3) (4) (5) (6) (7) (8) 


















 (0.0529) (0.192) (0.119) (0.0425) (0.0302) (0.150) (0.0932) (0.0740) 
Age         
50 – 79  1.120** 1.164 1.210** 1.047 1.035** 1.068 1.169** 1.136** 
 (0.0408) (0.165) (0.0869) (0.0413) (0.0135) (0.0492) (0.0594) (0.0454) 
         
_cons 31234.5 21970.2 27453.7 30081.8 8259.8 12508.8 26777.2 16984.5 
 (695.0) (2280.0) (1241.9) (1087.1) (60.25) (360.0) (823.8) (439.2) 
         
Log LH
♣
 -18630.4 -2819.12 -2669.44 -6498.78 -69110.9 -5228.22 -2775.36 -6429.56 
N 1629 251 235 572 6869 496 245 594 
Exponentiated coefficients; robust standard errors in parentheses(se) 
*
 p < 0.05, 
**
 p < 0.01, 
***
 p < 0.001 
♣ LH = Log likelihood  
♥ Reference groups are those without alcohol-related co-morbidities; age-group 18 – 49 
A46 – Erysipelas; E86 – Volume depletion; J459 – Asthma, unspecified; N10 – Acute tubulo-interstitial 
nephritis; R074 – Chest pain, unspecified;R101 – Pain  localized to upper abdomen; R509 – Fever, unspecified; 
R568 – Other  and unspecified convulsions 
 
5.6 Pain Localized to Upper Abdomen (R101) 
There were 1208 patients, of whom 1026 were non-alcoholic and 182 were alcoholic, were 
registered in NPR for treatment of upper abdominal pain in 2008 (table 4.2).  The LOS and 
cost variations for the treatment of 94 women and 88 men of the alcoholic group were 
compared to 618 women and 408 men of the control group respectively. The descriptive 
statistics displayed in table 4.2, table 4.4, table 5.1 and table 5.2 indicate that there was longer 
LOS and higher treatment cost for the alcoholic patients than for the non-alcoholic patients 




The two explanatory variables significantly explained the negative binomial regression model 
(NBR) for women with χ2(2) = 26.16 (p<0.001) (table 5.3) and men χ2(2) = 14.52 (p<0.001) 
(table 5.5). Moreover, the coefficients of the alcohol factor for both female and male models 
were significant. When other things are kept constant, the alcoholic women had 1.489 (se = 
0.241; p<0.05) times longer LOS than the non-alcoholic women, whereas the alcoholic men 
had 2.174 (se = 0.451; p<0.001) times longer LOS than the non-alcoholic men. This means 
there were 48.9% longer LOS for the alcoholic women and 117% longer LOS for the 
alcoholic men when compared to the corresponding non-alcoholic groups. The extreme 
variations among the men group were not understood. While there was longer average LOS 
for the alcoholic men, nothing outstanding (like extreme outliers) was discovered. Besides, 
the age factor was not found statistically significant in men’s model. In women’s model; 
ceteris paribus, the old women had 1.408 (se = 0.148; p<0.01) times longer LOS than the 
reference age-group (the young women). 
The cost variations for pain localized to upper abdomen was consistent with LOS for male. 
The GLM regression result in table 5.6 indicates that the treatment cost for the alcoholic men 
was 1.551 (se = 0.150; p<0.001) times higher than the treatment cost for non-alcoholic men 
(NOK 12508.8, se = 360). But the cost variation was not big as LOS variation among male. 
The cost variations among the female was not found significant at 5% level. The age factor 
had positive effect for both genders and it was significant amongst females only. 
5.7 Unspecified Fever (R509)  
While unspecified fever is not life threatening condition by itself to the adults, the underneath 
conditions causing the fever could be. Therefore, patients are sometimes hospitalized when 
figuring out what is causing for the fever. 478 patients, whom were admitted in public 
hospitals in Norway during 2008, were recorded in NPR. 98 of these patients, of whom 52 
were men and 46 were women, were also treated from alcohol related diagnoses, and 
therefore identified them as alcoholic group (table 4.1).  
The Average LOS of hospitalization for the treatment of the unspecific fever diagnosis was 
slightly longer for the non-alcoholic group than for the alcoholic group for both age-groups of 
men and the young age-group of women (table 4.3, table 4.4, and table 5.1). The negative 
binomial regression tests indicate also longer LOS for the non-alcoholic group than for the 
non-alcoholic group. However, neither alcohol nor age factor were found statistically 




Contrary to the shorter LOS for the alcoholic than for the non-alcoholic, the treatment cost of 
the unspecified fever was higher for the alcoholic for both female and male (table 4.3; table 
4.4; table 5.2). Moreover, the GLM regression result for male model indicates statistically 
significant higher treatment cost for the alcoholic male (table 5.6). The old male also had 
higher treatment cost of the unspecified than young male, with 1% level of significance. 
However, in case of female model, neither alcohol nor age factor was found statistically 
significant (table 5.4). 
5.8 Unspecified Convulsions (R568) 
1008 individuals, who were accepted in hospital care during 2008 for the treatment of 
unspecified convulsions and recorded in NPR, were included in the analysis. As other 
diagnoses above, smaller sample size for the alcoholic group was found. There were only 166 
patients, who in addition to the unspecified convulsion, were treated from diseases related to 
alcohol as well. 104 of them were male and 52 were female (table 4.1). A comparison of LOS 
and cost variations between those treated from alcohol related illness and those who were not 
diagnosed with such illness was made separately for female and male.  
Table 4.3, 4.4, 5.1 and table 5.2 were displayed the mean and standard deviation of cost and 
LOS for both genders. The later two tables include age factor as well. The results displayed in 
table 5.1 and table 5.2 show that there were longer LOS and higher cost of treatment for those 
patients who were identified as alcoholic (also treated from the alcohol-related diseases) for 
both genders.  
The NBR results also indicate that, other things being constant, there was 47.5% and 20.6% 
longer LOS for the alcoholic men and women respectively than for the non-alcoholic men and 
women (table 5.3; table 5.5). However, only the variations among men groups were found 
statistically significant at 5% level of significance (1.475 times longer: SE = 0.231; p<0.05). 
The effect of the age factor was found significant among the women. When other things are 
kept constant, the old women had 1.372 (se = 0.165; p<0.01) times longer LOS than the 
young women. The cost regression results in table 5.4 and table 5.6 indicate the higher 
treatment cost for the alcoholic patients was not significant at 5% level among the females, 
but it was significant at 1% level among males. The old age-group had higher treatment cost 





6.  Discussion 
Economic loss due to alcohol consumption is estimated to be substantial throughout the 
world, yet there are difficulties of capturing the true fraction of economic loss attributable to 
alcohol consumption (Baumberg, 2006). This is mainly due to the multiple risk factors and 
complex causation model. In addition, little evidence about the relationship between cost 
behavior of many diseases and harms and some risk factors (alcohol in this case), which are 
not directly related to the causation of the specific diseases in question, complicate the cost 
estimation methods. Even though the risk factor (alcohol in this case) may not be related 
directly to the occurrence of the disease, but it might indirectly affect the treatment process. 
 In order to develop proper policy response to the risk factors, finding the true societal cost is 
an important engine. The main objective of this study was to enlighten and observe whether 
there is a cost aspect, which is not commonly taken into consideration when estimating the 
economic cost of alcohol. It was compared two groups of patients (Alcoholic – those with 
alcohol co-morbidity and non-alcoholic – those without alcohol-related diseases). The 
hospital treatment cost and the length of hospital stay (LOS) of 8 diagnoses were analyzed. 
The case group, which was the group identified as an alcohol consumers based on diagnostic 
history (patients with alcohol co-morbidity), was compared to a control group (patients 
without alcohol-related diseases).  
Both the descriptive statistics as well as the regression results indicated longer LOS and 
higher treatment cost for the alcoholic group for all diagnoses except the unspecified fever. 
Five out of the eight diagnoses analyzed in this study were found statistically significant 
longer LOS for patients identified with history of alcohol-related diagnoses for both women 
and men. Diagnoses like erysipelas (A46), unspecified asthma (J459), acute tubule-interstitial 
nephritis (N10), unspecified chest pain (R074), and pain localized to upper abdomen (R101) 
had statistically significant longer LOS for women with alcohol-related diagnoses than 
women without these diagnoses (table 5.3). Men identified as alcoholic (based on alcohol-
related diagnoses) were found to have longer LOS for diagnoses like erysipelas (A46), 
volume depletion (E86), unspecified chest pain (R074), pain localized to upper abdomen 
(R101),  and other unspecified convulsion(R568) than  men who were assumed to be non-
alcoholic (table 5.5). Three of these diagnoses were found significant for both women and 
men. However, variation of LOS was wider among the women than among the men for two 




pain localized to upper abdomen (R101) was relatively wider among males than among the 
females.  
The generalized linear regression model for treatment cost was consistent with the findings of 
LOS variation. Statistically significant higher treatment cost for the alcoholic (those with 
alcohol-related co-morbidity) was found among the men for all of the 8 diagnoses (table 5.6). 
Amongst the women, 4 diagnoses, all of which were found significant variation for LOS 
model, were also found statistically significant higher treatment cost for those with alcohol-
related co-morbidity (table 5.4). It was only the pain localized to upper abdomen (R101) 
diagnosis that cost and LOS models were not consistent among women. Statistically 
significant cost and LOS variations between females and males were not found except the 
acute tubule-interstitial nephritis (N10), which males had a little higher treatment cost than 
females (Appendix-A.I-Table 8-1; Table 8-2). 
There are important points that have to be taken under consideration while interpreting the 
results of this study. The selection process of identifying patients into two groups as well as 
diagnostic selection suffers selection bias. As explained in the methods and study design 
section, diagnoses that are fully attributable to alcohol (Appendix-A.II-Table 8.3) as well as 
those diagnoses that are only partially attributable to alcohol (Appendix-A.II-Table 8.4) were 
used to identify a patient as an alcoholic (Alcohol co-morbidity). Difficulties in finding 
observations to compare the two groups were the main reason for including the partially 
alcohol-attributable diseases. How much these would affect the result of the study is 
unknown. Moreover, it was difficult to measure the pure effect of alcohol on non-alcohol 
related diseases since there was no record of drinking habit. The use of alcohol-related co-
morbidity as a means to distinguish patients says more about the effect of co-morbidity rather 
than alcohol. However, a sensitivity analysis (applying only the 100% alcohol-attributable 
diagnoses in table 8.3 for distinguishing the two groups) was done on unspecified chest pain 
(R074) diagnosis. This diagnosis had 57 observations for those with pure alcohol-related co-
morbidity and 6,812 observations for control group. The result was consistent as shown in the 
appendix-A.III-table 8.5. 
The selection process of the 8 diagnoses analyzed in this study was not also systematic. A 
minimum observations for the both groups was simply set (n>=100) and applied. This did not 
hold after collapsing the dataset in order to aggregate the patients with multiple observations. 




different diagnoses, the fact that these diagnoses included in this study indicated higher 
treatment cost and longer LOS for alcoholic would not be affected by the selection of any 
other diagnoses. But again the selection process of these 8 diagnoses was merely a convenient 
way rather than a random systematic method.  
The finding of this study was not based on randomized controlled trail. Cost and time 
constrained for performing such kind of study. It was rather a retrospective observational data 
and many important factors (unobservable heterogeneity) that could explain a lot of the 
variations of the LOS and cost were missing. Smoking, diet, training habit, and genetic and 
environmental factors are among the most important factors that could have changed the 
results. Studies indicate that smokers consume more alcohol than non-smokers (Rimm et al., 
1995; Reed et al., 2007). Studies also indicate that smoking and alcohol are common risk 
factors to many diseases (Mukamal, 2006). This means most of the diseases that are partially 
attributable to alcohol (Table 8-4), which were used for group identification, are also 
attributable to smoking. Genetic as well environmental factors could also be the cause of the 
co-morbidities assumed to be alcohol-related diseases. This implies that lifestyle of the 
individual as well as environmental and genetic factors could have an impact on both the 
occurrences of the disease as well as the recovering process. Other factors like adverse effects 
due to misdiagnosis, mistreatment, and treatment side effects were not also available to 
consider.  Moreover, reasons a patient remained in hospital bed were assumed to be for the 
same specific diagnosis under consideration.  
These missing features also called omitted variables, which are individual specific character, 
were not included in the analysis. Instead, these unobservable heterogeneities were assumed 
to be random for all patients. This means the study had potential parameter bias known as 
unobserved heterogeneity bias. It was difficult to deal such kind of bias, since these factors 
were not available it was impossible to include for control. However, in case of the LOS, the 
negative binomial regression model applied, considers overdispersion by including a random 
term (ε), and this minimizes unobserved heterogeneity amongst the individuals (Long and 
Freese, 2006). 
Another barrier was lack of enough observations suitable for comparison. The sample size of 
the case group was relatively very small compared to the control group for all diagnoses 
considered in this study. The unequal cell size is common to almost all studies including 




In addition to the problem of unequal variances, this restricted, to further categorize the 
individual age-groups. Because of the fewer observations of the age-groups below 40 years, 
age-category was divided only into two groups, that is, below 50 and above 50. This was done 
to minimize the problem of empty cells. While this categorization helped to execute statistical 
models, there is high possibility it widened the problem of unobservable heterogeneity. 
However, a sensitivity analysis of the age category is conducted by dividing the age into 
seven categories (the results displayed in the appendix A.IV), and no significant changes were 
observed.  
The potential misspecification error of the models could also affect the estimated parameters. 
Because of the relaxations of the assumptions of the ordinary least square models, the 
generalized linear regression models’ parameter estimations could be inefficient and 
imprecise compared to the ordinary least square models (Buntin and Zaslavsky, 2004). 
While these limitations could affect the variations of LOS and cost analyzed in this study, the 
importance of the issues raised in this study is incontestable. The under estimation of the 
economic burden of alcohol could be higher than expected. The need of well organized 















7.  Conclusion 
Alcohol involves with many diseases as risk factor either wholly or partially (Rehm et al., 
2009), the economic loss attributable to alcohol is substantial (Baumberg, 2006; 
Thavorncharoensap et al., 2009). Yet, there are doubts as to whether the economic cost of 
alcohol is estimated accurately because of intricate multidimensional associations between 
alcohol use and health conditions related to it (Rehm et al., 2010). Moreover, alcohol-related 
diseases co-occur with other non-alcohol-related diseases, which further complicate the 
treatment and recovering process from both alcohol-related and non-alcohol-related diseases. 
Co-morbidity of diseases is common and associated with increased health care costs (Fortin et 
al., 2007a; Fortin et al., 2007b; Valderas et al., 2009). This makes the estimation of economic 
burden of alcohol even more obscure. It also seems that in cost benefit analysis studies of 
alcohol, the effect of alcohol to non-alcohol related diseases when co-morbidity happens is 
not usually considered. 
The result of this study indicates that patients with alcohol-related diseases had higher 
treatment cost with longer length of hospital stay (LOS) for the treatment of the non-alcohol-
related diagnoses when compared to other patients who had not alcohol-related diagnosis. If 
this is the case it means a crucial portion of the economic burden of alcohol is disregarded, 
implying underestimation of the social cost burden of alcohol. It is difficult to generalize the 
result of this finding, because of the limitations and important missing factors. However, the 
findings of this study could be used as benchmark to further investigate and study how 
alcohol indirectly affects the treatment cost of other non-alcohol related diagnoses. Important 
factors are always missing from the economic cost estimates of alcohol and other substances 
abuse (NIAAA, 2000) this necessitates continuous development and reformation of cost 
estimation methods as well as factor considerations (Single, 2009).  
In a nutshell, there are so much that is not yet discovered about the economic and social 
burden of alcohol. A much broader perspective of the cost estimates and constant researches 
on alcohol-attributable burden is recommended.  Any future research in this area is also 


















A.I. NBR and GLM with gender variable included  
 
Table 8-1: The effect of alcohol (alcohol-related diseases) for the LOS of 8 diagnoses and variation by gender 
 (1) (2) (3) (4) (5) (6) (7) (8) 
LOS A46 E86 J459 N10 R074 R101 R509 R568 
















 (0.0675) (0.127) (0.244) (0.0626) (0.0444) (0.236) (0.113) (0.171) 
Gender
♥
         
Female 1.021 1.095 1.054 0.923 0.982 1.064 1.222 1.159 
 (0.0418) (0.117) (0.111) (0.0442) (0.0208) (0.0900) (0.129) (0.0903) 
Age
♥
         
50 – 79  1.436*** 1.576*** 1.535*** 1.466*** 1.110*** 1.267** 1.230 1.280** 
 (0.0620) (0.199) (0.141) (0.0667) (0.0250) (0.108) (0.133) (0.102) 
















 (0.153) (0.300) (0.181) (0.203) (0.0185) (0.0955) (0.331) (0.108) 
         
N 2575 596 718 1858 12664 1208 478 1008 
Exponentiated coefficients; robust standard errors in parentheses 
♥ Reference groups are those without alcohol related diagnoses; male; age-group 18 – 49 
*
 p < 0.05, 
**
 p < 0.01, 
***
 p < 0.001 
 
Table 8-2: The effect of alcohol (alcohol-related diseases) for the treatment cost of 8 selected diagnoses 
 (1) (2) (3) (4) (5) (6) (7) (8) 
Cost A46 E86 J459 N10 R074 R101 R509 R568 


















 (0.0449) (0.101) (0.329) (0.0270) (0.0223) (0.0997) (0.0711) (0.0591) 
Gender♥         
Female 1.013 0.868 1.048 0.944
**
 0.991 1.023 1.045 0.966 
 (0.0266) (0.0636) (0.0564) (0.0195) (0.00943) (0.0364) (0.0467) (0.0327) 
Age♥         
50 – 79  1.122*** 1.353*** 1.128* 1.134*** 1.027** 1.125** 1.145** 1.113*** 
 (0.0302) (0.112) (0.0632) (0.0215) (0.00995) (0.0476) (0.0526) (0.0358) 
         
_cons 31197.3 20651.2 27604.6 28251.2 8298.9 12513.9 27346.7 17167.4 
 (628.0) (1670.2) (1529.8) (625.4) (58.21) (317.0) (842.2) (431.2) 
         
Log LH
♣
 -29476.9 -6642.86 -8175.19 -20967.3 -127369.9 -12733.9 -5424.78 -10892.3 
N 2575 596 718 1858 12664 1208 478 1008 
Exponentiated coefficients; robust Standard errors in parentheses 
*
 p < 0.05, 
**
 p < 0.01, 
***
 p < 0.001 
♣ LH = Log likelihood  
♥ Reference groups are those without alcohol related diagnoses; male; age-group 18 – 49 
A46 – Erysipelas; E86 – Volume depletion; J459 – Asthma, unspecified; N10 – Acute tubulo-
interstitial nephritis; R074 – Chest pain, unspecified;R101 – Pain  localized to upper abdomen; R509 





A.II. Alcohol attributable diseases used for identification of 
groups 
 
Table 8-3: Diseases 100% attributable to alcohol consumption, which are used for group identification 
ICD-10 Health Condition 
F10-F10.9 Mental and behavioral disorders due to use of alcohol 
G31.2 Degeneration of nervous system due to alcohol 
G62.1 Alcoholic polyneuropathy 
G72.1 Alcoholic myopathy 
I42.6 Alcoholic cardiomyopathy 
K29.2 Alcoholic gastritis 
K70 Alcoholic liver disease 
K85.2 Alcohol-induced acute pancreatitis 
K86.0 Chronic pancreatitis (alcohol induced) 
O35.4 Maternal care for (suspected) damage to fetus from alcohol 
Q86.0 Fetal alcohol syndrome (dysmorphic) 
R78.0 Finding of alcohol in blood 
T51.0-T51.1 Ethanol poisoning & Methanol poisoning 
T51.8-T51.9 Toxic effect of alcohol, unspecified 
Y90 Evidence of alcohol involvement determined by blood alcohol level 














Table 8-4: Diseases that are partially attributable to alcohol consumption, which are used for group  identification 
ICD-10 Health Condition 
A15-A19, B90 Tuberculosis 
B20-B24 Human immunodeficiency virus/acquired immune 
deficiency syndrome (HIV/AIDS) 
C00-C13 Malignant neoplasm of lip, oral cavity and pharynx 
C15-C16 Malignant neoplasm of oesophagus 
C18-C22 Malignant neoplasm of colon; Malignant neoplasm 
of rectum; Malignant neoplasm of liver and 
intrahepatic bile ducts 
C33-C34 Trachea, bronchus and lung cancer 
C50 Malignant neoplasm of breast 
D00-D48 Other neoplasms 
E10-E13 Diabetes mellitus 
F01-F03;G30,G31 Alzheimer’s disease and other dementias 
F32, F33, F34.1 Unipolar depressive disorders 
G40-G41 Epilepsy and Status epilepticus 
I11-I13 Hypertensive heart disease 
I20-I25 Ischaemic heart disease 
I42 Cardiomyopathy 
I47-I48 Conduction disorders and other dysrhythmias 
I60-I67;I69.0-I69.3 Ischaemic stroke; Haemorrhagic and other non-
ischaemic stroke 
J09-J22;J85 Lower respiratory infections: pneumonia 
K20–K22, K28–K31, K38, 
K57–K63, K75.2, K75.3, 
K75.4, K76–K77, 




Other digestive diseases 
L40-L41 Psoriasis 
O00-O008 Abortion 










Table 8-5 : The effect of alcohol (100% alcohol-related diseases) for the LOS for unspecified chest pain among men 
 (LOS) (Cost) 
 R074 R074 






 (0.338) (0.147) 
Age   
50 – 79  1.153*** 1.049*** 
 (0.0322) (0.0134) 




 (0.0217) (70.87) 




 (0.0271)  
N 6869 6869 
Exponentiated coefficients; Standard errors in parentheses 
*
 p < 0.05, 
**
 p < 0.01, 
***
 p < 0.001 
♥ nonalcohol group; Age group 18 – 49 as reference group 





A.IV. NBR and GLM Models for seven age groups 
 
Table 8-6: The variations of LOS among seven age groups 
 (1) (2) (3) (4) (5) (6) (7) (8) 
LOS A46 E86 J459 N10 R074 R101 R509 R568 














 (0.0691) (0.126) (0.229) (0.0606) (0.0442) (0.226) (0.109) (0.159) 
Gender♥         
female  0.999 1.103 1.074 0.956 0.974 1.064 1.214 1.140 
 (0.0411) (0.112) (0.108) (0.0448) (0.0208) (0.0891) (0.127) (0.0879) 
age♥         
20 – 29  1.072 1.629 1.142 1.089 1.200 1.090 0.912 0.910 
 (0.245) (0.572) (0.326) (0.0987) (0.167) (0.171) (0.275) (0.160) 
         
30 – 39  1.422 1.700 1.664* 1.127 1.612*** 1.256 1.010 1.004 
 (0.314) (0.607) (0.409) (0.103) (0.211) (0.195) (0.288) (0.174) 
         
40 – 49  1.622* 1.798 1.617* 1.358*** 1.766*** 1.302 1.123 1.504* 
 (0.356) (0.628) (0.396) (0.119) (0.228) (0.212) (0.302) (0.271) 
         
50 – 59  1.830** 1.992* 1.933** 1.461*** 1.753*** 1.312 1.295 1.356 
 (0.396) (0.643) (0.471) (0.127) (0.226) (0.218) (0.335) (0.242) 
         
60 – 69  2.162*** 2.916*** 2.715*** 1.602*** 1.788*** 1.710** 1.139 1.655* 
 (0.467) (0.935) (0.682) (0.140) (0.231) (0.282) (0.291) (0.329) 
         
70 – 79  2.290*** 2.653** 2.425*** 2.019*** 2.039*** 1.619** 1.429 1.420* 
 (0.497) (0.809) (0.598) (0.173) (0.266) (0.260) (0.380) (0.251) 
         
_cons 2.706
***









 (0.575) (0.449) (0.273) (0.263) (0.0754) (0.150) (0.746) (0.257) 


















 (0.0262) (0.0658) (0.0672) (0.0252) (0.0206) (0.0774) (0.0609) (0.0573) 
N 2575 596 718 1858 12664 1208 478 1008 
Exponentiated coefficients; Standard errors in parentheses 
*
 p < 0.05, 
**
 p < 0.01, 
***
 p < 0.001 
♥ Reference groups are those without alcohol related diagnoses; male; age-group 18 – 19 
A46 – Erysipelas; E86 – Volume depletion; J459 – Asthma, unspecified; N10 – Acute tubulo-interstitial nephritis; R074 – 








Table 8-7: The treatment cost variation between seven age groups 
 (1) (2) (3) (4) (5) (6) (7) (8) 
Cost A46 E86 J459 N10 R074 R101 R509 R568 


















 (0.0476) (0.0971) (0.282) (0.0268) (0.0222) (0.0919) (0.0667) (0.0590) 





 0.990 1.023 1.045 0.962 
 (0.0271) (0.0604) (0.0541) (0.0202) (0.00937) (0.0343) (0.0434) (0.0327) 
Age♥         
20 – 29  0.957 1.495* 1.097 1.048 1.014* 0.984 1.160* 0.986 
 (0.0793) (0.261) (0.108) (0.0377) (0.00650) (0.0544) (0.0801) (0.0715) 
         
30 – 39  1.134 1.263 1.056 1.096* 1.057*** 0.987 1.204** 1.061 
 (0.0948) (0.227) (0.0810) (0.0448) (0.0112) (0.0536) (0.0707) (0.0774) 
         
40 – 49  1.104 1.553* 1.153 1.079* 1.088*** 1.133 1.178** 1.146 
 (0.0891) (0.294) (0.111) (0.0379) (0.0105) (0.0769) (0.0694) (0.0862) 
         
50 – 59  1.131 1.841*** 1.151 1.154*** 1.092*** 1.068 1.320*** 1.141 
 (0.0909) (0.316) (0.0964) (0.0445) (0.00866) (0.0685) (0.105) (0.0846) 
         
60 – 69  1.226* 2.016*** 1.392* 1.201*** 1.110*** 1.164* 1.353*** 1.169* 
 (0.0978) (0.363) (0.180) (0.0480) (0.0146) (0.0862) (0.0805) (0.0823) 
         
70 – 79  1.322** 1.893*** 1.193* 1.256*** 1.087*** 1.291* 1.341*** 1.284** 
 (0.120) (0.293) (0.104) (0.0486) (0.0126) (0.134) (0.0814) (0.103) 


















 (2208.8) (2214.6) (2122.6) (1031.0) (34.24) (672.1) (925.5) (1047.4) 
N 2575 596 718 1858 12664 1208 478 1008 
Exponentiated coefficients; Standard errors in parentheses 
*
 p < 0.05, 
**
 p < 0.01, 
***




A.V. Normality and Distribution  
 
 
The length of hospital stay distribution and residuals normality for Erysipelas diagnosis 
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The length of hospital stay distribution and residuals normality for volume depletion diagnosis 
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The length of hospital stay distribution and residuals normality for asthma (unspecified) diagnosis 
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The length of hospital stay distribution and residuals normality for chest pain (unspecified) 
diagnosis 
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The length of hospital stay distribution and residuals normality for fever (unspecified) diagnosis 
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The cost distribution and residuals normality for Erysipelas diagnosis 
 
 













































































The cost distribution and residuals normality for asthma (unspecified) diagnosis 
 
 
























































































































































The cost distribution and residuals normality for fever (unspecified) diagnosis 
 
 










































































A.VII. Alcohol consumption and Burden attributable to alcohol 
consumption 
Table 8-8: Mortality, Road traffic fatalities involving alcohol 
  Road traffic fatalities involving alcohol (% of all road traffic fatalities) 
Location 2007 2006 2005 2004 2003 2002 
Australia   25.0 27.0 21.0   22.0 
Austria 7.8 7.5 7.3 7.6 8.8 9.5 
Belgium 5.6 5.0 3.5 3.0 6.0 6.7 
Bulgaria 4.4 3.8 4.9 4.6 5.9 5.6 
Canada 32.4 32.7 29.9 30.5 32.4 29.6 
China   4.2       1.5 
Cyprus 18.0 17.4 22.6 20.5 8.3 10.6 
Czech Republic 3.4 4.5 5.5 4.9 8.8 11.0 
Denmark 27.6 23.9 25.7 28.7 24.3 28.5 
Estonia 49.5 42.2 37.7 34.7 36.6 39.0 
Fiji         21.0   
Finland 24.0 26.2 23.5 22.4 17.7 21.9 
France 29.4 28.9 28.8 31.4 31.7 30.3 
Germany 11.4 11.8 11.3 12.1 12.4 13.6 
Greece 9.2 8.0 10.7 9.4 8.2 9.1 
Guam 44.0 38.5 44.0 43.0 25.0 46.0 
Honduras           6.0 
Hungary 13.1 13.4 12.8 14.5 11.6 13.4 
Ireland     28.8 28.3 35.5   
Israel 8.6 6.9 4.6 4.9 2.3 2.1 
Italy 3.7 2.8 2.1 2.7 2.2 1.7 
Latvia 21.7 20.6 21.7 21.9 22.4 28.6 
Lithuania 11.9 10.3 13.7 12.9 11.3 13.1 
Luxembourg       14.3 3.8 9.7 
Netherlands 4.0 3.0 4.8 3.6 3.1 4.7 
New Zealand 27.0 24.0 25.0 27.0 27.0 24.0 
Norway     22.3       
Poland 8.3 7.5 8.4 7.4 8.2 9.1 
Portugal 6.7 5.3 4.7 2.5 3.2 3.0 
Puerto Rico       50.0 48.0   
Republic of Korea     14.3 13.3 15.4 12.6 
Romania 8.0 8.2 7.3 1.0 1.1 0.5 
Slovakia 4.8 8.5 6.6 6.8 8.4 9.2 
Slovenia no data 47.7 36.8 42.3 39.7 40.9 
Spain 13.9 14.2 14.4 13.9 16.1 14.9 
Sweden 19.4 18.9 20.0 21.1 21.5 19.9 
Switzerland 14.3 15.7 19.3 20.2 19.4 18.1 
United States of America 37.9 . . 39.5 39.9 40.7 




Table 8-9: Mortality, Alcohol-related disease mortality 
  Alcohol-related disease mortality, per 100,000 (15+ years)  
Location Time 
Period 
Male Female Both sexes 
Czech Republic 2002 90.0 14.0 . 
Finland 2010 . . 29.3 
2009 . . 30.9 
2008 . . 30.0 
2007 . . 30.4 
2006 . . 27.5 
2005 . . 28.2 
2004 . . 23.9 
2003 . . 19.8 
2002 . . 31.7 
France 2002 75.0 18.0 . 
Germany 2010 27.9 9.3 18.4 
2009 27.0 8.8 17.7 
2008 27.7 9.3 18.3 
2007 27.7 8.9 18.1 
2006 28.7 9.5 18.9 
2005 30.3 9.7 19.8 
2004 30.4 9.6 19.8 
2003 31.6 10.1 20.6 
2002 31.8 10.1 20.7 
Guam 2003 . . 3.1 
Hungary 2002 216.0 50.0 . 
Iceland 2006 . . 5.0 
2005 . . 6.9 
2004 . . 4.8 
2003 . . 3.1 
2002 . . . 
Latvia 2009 . . 19.0 
2008 . . 14.0 
2007 . . 19.0 
2006 . . 21.0 
2005 . . 16.0 
Lithuania 2002 221.0 41.0 . 
Marshall Islands 2007 . . 29.0 
2006 . . 21.7 
2005 . . 33.9 
Mexico 2005 6.2 3.8 . 
2004 6.5 4.0 . 
2003 7.2 4.6 . 
2002 7.5 4.7 . 




2007 4.2 1.5 2.9 
2006 5.0 1.8 3.5 
Norway 2007 10.8 3.4 5.9 
2006 10.7 3.3 9.0 
2005 11.4 3.1 7.9 
2004 14.9 3.7 8.3 
2003 13.6 4.2 11.3 
2002 14.2 3.8 10.9 
Poland 2002 87.0 9.0 . 
Russian Federation 2002 290.0 47.0 . 
Slovenia 2007 118.2 35.9 76.5 
Sweden 2007 . . 10.9 
2006 . . 10.4 
2005 . . 10.9 
2004 . . 11.5 
2003 . . 11.2 
2002 27.0 5.0 14.1 
Ukraine 2004 281.5 72.2 167.4 
United Kingdom 2009 17.4 8.4 12.8 
2008 18.7 8.7 13.6 
2006   14.8   
2003 . . 11.6 
2002 37.0 13.0 . 




















 per 100,000  Mortality
3
 per 100,000 
  
Male Female Both Male Female Both 
Alcohol use disorder 1497 425 969 5.3 0.8 2.9 
Breast cancer 1 301 152 0,1 20 10.7 
Cerebrovascular 
disease 
316 253 283 41,5 34 37.3 
Colon and rectum 
cancers 
210 158 183 25.6 17.5 21 
Diabetes mellitus 178 173 175 8.7 5.4 6.9 
Drownings 57 24 40 2.6 0.9 1.7 
Falls 202 111 157 9 5.8 7.2 
Fires 34 15 25 1,3 0,7 1 
Ischaemic heart disease 725 254 482 103 48.3 72.7 
Liver cancer 15 9.4 12.2 2 1.4 1.7 
Liver cirrhosis 93 37 65 6.5 0.1 4.3 
Mouth and oropharynx 
cancer 
29 9 19 3.1 0.1 2 
Oesophagus cancer 36 12 24 4.6 0.1 2,9 
Poisoning 289 102 197 11.4 0.1 8 
Prematurity and low 
birth rate 
26 29 28 0.2 0 0.3 
Road traffic accidents 332 118 227 8.9 0.1 5.8 
Self-inflicted injury 348 162 256 14.7 0.2 10.7 
Other unintentional 
injuries 
338 181 261 9.6 3.8 6.6 
Violence 41 20 31 1,1 0 0,8 
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